CURRICULUM VITAE

> **WILLIAM DOUGLAS FIGG, SR**
>
> **Work Address:** National Institutes of Health
>
> National Cancer Institute
>
> Center for Cancer Research
>
> Medical Oncology Branch
>
> Molecular Pharmacology Section
>
> Building 10, Room 5A01, MSC 1910
>
> 9000 Rockville Pike
>
> Bethesda, Maryland 20892
>
> Telephone (301) 402-3623
>
> Mobile (240) 338-6898
>
> Fax (301) 402-8606
>
> Email wdfigg@helix.nih.gov
>
> **Education:**
>
> 8/81 - 5/83 Georgetown College, Georgetown, Kentucky,
>
> Major - Biology
>
> 8/83 - 11/86 Samford University, School of Pharmacy, Birmingham, AL
>
> **Bachelor of Science**
>
> 9/87 - 8/89 Auburn University, School of Pharmacy, Birmingham, AL
>
> **Doctor of Pharmacy**
>
> 5/01 - 7/03 Columbia University, School of Business, New York, NY and
>
> London Business School, University of London, London, UK,
>
> **Master of Business Administration**
>
> **Post-Graduate Training:**
>
> 11/86 - 9/87 Internship, University of Alabama Hospital, Birmingham,
> AL
>
> 6/90 - 6/92 Post-Doctoral Fellowship in Clinical Research/Drug
> Development,
>
> University of North Carolina at Chapel Hill, Chapel Hill, NC
>
> Revised -- 10 July 2008
>
> **Professional Appointments:**
>
> 6/83 - 11/86 Pharmacy Externship, Department of Pharmacy,
>
> BMC Princeton Hospital, Birmingham, Alabama (20 hrs/wk)
>
> 9/87 - 6/90 Clinical Pharmacist, Department of Pharmacy, University of
>
> Alabama Hospital, Birmingham, Alabama
>
> 6/90 - 6/92 Clinical Staff Pharmacist, Department of Pharmacy,
>
> Duke University Medical Center, Durham, North Carolina
>
> (12-20 hrs/wk)
>
> 7/92 - 7/95 Clinical Pharmacist, Pharmacy Department, Mary Washington
>
> Hospital, Fredericksburg, Virginia (8 hrs/wk)
>
> 7/92 - 8/93 Clinical Investigator, Clinical Pharmacokinetics Section,
>
> Clinical Pharmacology Branch, National Cancer Institute,
>
> Bethesda, Maryland
>
> 7/92 - present Senior Staff, Prostate Cancer Clinic, National Cancer
> Institute,
>
> Bethesda, Maryland
>
> 9/93 - 12/96 Senior Investigator, Section Head, Clinical
> Pharmacokinetics
>
> Section, CPB, DCS, NCI; and Deputy Branch Chief, Clinical
>
> Pharmacology Branch, Division of Clinical Sciences, National
>
> Cancer Institute, Bethesda,Maryland
>
> 12/96 - 2/01 Senior Investigator and Head, Clinical Pharmacokinetics
> Section,
>
> Developmental Therapeutics Department, Medicine Branch, Division
>
> of Clinical Sciences, National Cancer Institute, Bethesda, Maryland
>
> 2/01-11/05 Principle Investigator and Head of the Molecular
> Pharmacology
>
> Section, Cancer Therapeutics Branch, Center for Cancer Research,
>
> National Cancer Institute; and Head of the Clinical Pharmacology
>
> Scientific Core, Medical Oncology Clinical Research Unit, CCR,
>
> NCI; and Head of the Preclinical Pharmacokinetics Core, Molecular
>
> Targets Program, CCR, NCI
>
> 11/05 - present Senior Scientist and Head of the Molecular
> Pharmacology Section, Medical Oncology Branch, Center for Cancer
> Research, National Cancer Institute; and Head of the Clinical
> Pharmacology Program, MOB, CCR, NCI; and Head, Biological Fluid
> Processing Core, CCR, NCI, National Institutes of Health, Bethesda,
> Maryland
>
> **Professional Licensure:** Alabama State Board of Pharmacy #11217 (15
> Sept 1987)
>
> Tennessee State Board of Pharmacy #007039 (21 May 1987)
>
> North Carolina State Board of Pharmacy #11089 (18 Sept 1990)
>
> Virginia State Board of Pharmacy #0202011192 (19 Oct 1993)
>
> **Board Certification:** Pharmacotherapy Specialty #291192 (8/91)
>
> recertification 12/99
>
> recertification 12/07
>
> **Academic Appointments/Affiliations/Teaching Responsbilities:**
>
> Lecturer - Howard University Pharm.D. Program (Oncology Module in
> Therapeutics course), 1995
>
> Lecturer - Shenandoah University Pharm.D. Program
>
> (Oncology Module in Therapeutics course), (1999-2000)
>
> Graduate Advisor - University of Pittsburgh School of Pharmacy, School
> of Pharmacy (1996-1999)
>
> Adjunct Professor - University of Maryland School of Pharmacy
> (1994-present)
>
> Adjunct Clinical Professor -- University of Kentucky School of
> Pharmacy (1993--1999)
>
> Clinical Pharmacology Consultant -- Johns Hopkins University
> (1999--2000)
>
> Adjunct Clinical Associate Professor -- University of Michigan School
> of Pharmacy (2003--present)
>
> Affiliate Professor and Graduate Advisor - Virginia Commonwealth
> University,
>
> Medical College of Virginia, School of Pharmacy, Department of
> Pharmaceutics (1997-present)
>
> Lecturer -- Columbia University, School of Public Health,
>
> Course - Strategic Management and Healthcare Policy (2004-2007)
>
> Graduate Advisor -- Oxford University (2005 -- present)
>
> Graduate Advisor -- George Washington University, Department of
> Genetics (2004 -- present)
>
> Graduate Advisor -- University of Maryland, Molecular and Cell Biology
> Program (2006 -- present)
>
> Graduate Advisor -- Johns Hopkins University (2008 -- present)
>
> **United State Public Health Service Commissioned Corps.:**
>
> US Public Health Service Commissioned Officer 0-3 (Lt.), 7/92-12/93
>
> US Public Health Service Commissioned Officer 0-4 (Lt. Commander),
> 1/94 - 12/98
>
> US Public Health Service Commissioned Officer 0-5 (Commander), 1/99 --
> 6/06
>
> US Public Health Service Commendation Medal, 1995
>
> US Public Health Service Commissioned Corps Unit Commendation, 2004
>
> US Public Health Service Commissioned Corps Bicentennial Unit
> Commendation, 1998
>
> US Public Health Service, Pharmacy Professional Advisory Committee
> (1997 - 2000)
>
> Subcom. on Pharmaceutical Care (1995 - 1998)
>
> Chair, Subcommittee on Pharmaceutical Care (1998 - 2000)
>
> Liason to ACCP (2005 -- present)
>
> US Public Health Services Commissioned Corps Medical Review Board
> (2002)

US Public Health Commissioned Corps Readiness Force

> Basic Response Readiness Certified (2005 -- present)
>
> US Public Health Commissioned Corps Assimilation into the Regular
> Corps, 2007
>
> Deployed to Meridian, Mississippi in Response to Hurricane Katrina --
>
> Command Staff, Head of Logistics
>
> US Public Health Service Commissioned Corps Citation Medal, 2005
>
> US Public Health Service Commissioned Corps Crisis Response Service
> Award
>
> Gulf Coast Hurricanes, 2005
>
> US Public Health Service Commissioned Officer 0-6 (Captain), 7/06 --
> present
>
> US Public Health Service Commissioned Corps Citation Medal, 2006
>
> US Public Health Service Commissioned Corps Commendation Medal, 2006
>
> US Public Health Service Commissioned Corps OCCO Board (one year
> appointment)
>
> US Public Health Service Commissioned Corps Functional Group
> Transformation Team
>
> (Research Category)
>
> US Public Health Service Commissioned Corps Outstanding Unit Citation,
> 2007
>
> **Professional Affiliations:**
>
> American Society of Health-System Pharmacist (1986 -- 1992, 2005 -
> present)
>
> Abstract Reviewer (1992-2001)
>
> American College of Clinical Pharmacy (1990 - present)
>
> Research Affairs Committee (1992 - 1994)
>
> Chairman of Abstract Selection Committee (1997)
>
> Abstract Reviewer for Oncology Submission (1996 - present)
>
> Program Committee, 1997 Annual Meeting
>
> Awards Committee (1997-1999)
>
> Chair, Subcommittee on the Young Investigator's Award (1998-1999)
>
> Task Force on Science (1999 - 2001)
>
> Fellowship Credential Committee (2001 - 2002)
>
> Research Institute Trustee -- Elected member (2003 -- 2006)
>
> Chair, Grants and Fellowship Selection Committee (2006)
>
> American Society for Clinical Pharmacology and Therapeutics (1991 -
> present)
>
> American College of Clinical Pharmacology (1992 - present)
>
> Chairman Government Advisory Board (1995 - 1997)
>
> Program Committee, 1999 Annual Meeting
>
> Abstract Reviewer (1999)
>
> American Association for Cancer Research (1993 - present)
>
> EORTC/NCI/AACR program committee (2007)
>
> Abstract Reviewer EORTC/NCI/AACR meeting (2007)
>
> Scientific Committee 20^th^ EORTC/NCI/AACR Molecular Targets and
>
> Cancer Therapeutics Symposium
>
> American Society of Clinical Oncology (1993 - present)
>
> Abstract Reviewer (2000)
>
> Program Committee (2000)
>
> American Urological Association (1998 - present)
>
> Association of Military Surgeons of the US (1998 - present)
>
> American Association of Pharmaceutical Science (2005 -- present)
>
> American Pharmacists Association (2005 -- present)
>
> Hematology/Oncology Pharmacy Association (2005 -- present)
>
> **Professional Activities/Committees (intramural and extramural):**
>
> National Institutes of Health, Pharmacy and Therapeutics Committee,
>
> NCI Representative (1994 - present)
>
> Board of Pharmacotherapy Specialty, Item Writer for Exam (1991 - 1994)
>
> National Association of Boards of Pharmacy Licensure Examination, Item
> Writer (1996)
>
> Howard Hughes Medical Institute Scholars Program, Selection Committee
> (1996, 1998)
>
> Advisory Comm. for Endocrinology Section, National Institute of Child
> Health and
>
> Human Development (1997)
>
> Head, Clinical Pharmacology Special Interest Group, National
> Institutes of Health (1997 - 1998)
>
> Head, Clinical Pharmacology Special Interest Subgroup in Oncology
> (1998 - 2002)
>
> NCI's Prostate Cancer Task Force (1997 - 1998)
>
> NCI's Prostate Cancer Progress Review Group (1997 - 1998)
>
> 2003 Committee to Evaluate the progress of the 1998 Prostate PRG
>
> Co-Chair, NCI's Tumor Angiogenesis and Invasion Think Tank (1998 -
> 2002)
>
> NCI\'s Ad Hoc Tenure and Promotion Committee Reviewer (1999)
>
> American Association of Pharmaceutical Scientists - Visiting Scientist
> --
>
> MCV School of Pharmacy (2000)
>
> US Pharmacopeia, Scientific Advisory Board for Oncology (2000 - 2003)
>
> NCI, CCR's Early Drug Development Committee (2004 -- 2005)
>
> NCI, CCR's Tissue Repository Committee (2004-2005)
>
> NCI's Protocol Monitoring and Review Committee, Ad Hoc Clinical
> Pharmacology Reviewer
>
> (2000 - 2002)
>
> NCI\'s Medical Oncology Branch Protocol Review Committee (1999 - 2001)
>
> NCI\'s Cancer Therapeutics Branch Protocol Review Committee (2001 -
> 2005)
>
> NCI's Medical Oncology Branch Protocol Review Committee (2006 --
> present)
>
> NCI\'s Vascular Biology Faculty -- Steering Committee (2001 - present)
>
> Co-Chair, NCI\'s Vascular Biology Faculty (2001 - 2004)
>
> Chair, NCI's Vascular Biology Faculty (2005 -- 2006)
>
> NCI\'s GU Malignancy Faculty -- Steering Committee (2001 - present)
>
> NCI\'s Molecular Target Faculty -- Steering Committee (2002 - present)
>
> NCI\'s Institutional Review Board (2002 - 2004)
>
> NCI's Technology Review Group (2005 -- present)
>
> NCI's Joint Drug Development Committee, voting member (2005 --
> present)
>
> NCI's Pharmacodynamic Endpoint Meeting -- Chaired (2006)
>
> NCI's Molecular Target Prioritization Meeting -- Chaired (2006)
>
> NCI's Drug Development Prioritization Meeting -- Chaired (2006)
>
> NCI's Medical Oncology Chief Search Committee (2006)
>
> NIH's Scientific Directors Ad Hoc Committee on Biological Samples
> (2006-2007)
>
> NIH's Clinical Pharmacology Program and Course -- Steering Committee
> (2006 -- present)
>
> NCI's Friday Medical Oncology Lecture Series (co-coordinator) (2005 -
> present)
>
> NCI's Prostate Cancer Teaching Conference (coordinator) (1987 --
> present)
>
> NCI's Molecular Target Development Program (review committee) 2007
>
> 2008 7^th^ Annual NIH Oxford/Cambridge Colloqium -- Program/Organizing
> Chair
>
> NCI's Molecular Targets Development Program -- Chair of the Steering
> Committee
>
> **Editorial Appointments/Activities:**
>
> Assistant Editor 1991-present DrugDex Information Systems (MicroMedex)
>
> Editorial Board 1997-present Pharmacotherapy
>
> External Advisory Board 1994-2001 Physician Data Query, Clinical Trial
> Database
>
> Editorial Board 1994-1997 Oncology Report
>
> Editorial Board 1995-present Journal of Clinical Pharmacology
>
> Editorial Board 1997-2001 The Prostate Journal
>
> Associate Editor 1999-present Clinical Cancer Research
>
> Editorial Board 2000-present The Journal for Drug Evaluation
>
> Editorial Board 2000 Pediatric Drug Therapy
>
> Section Editor 2000-2005 Clinical Prostate Cancer
>
> Editorial Board 2001-present Cancer Biology and Therapy
>
> Editorial Board 2002-present International Journal of Cancer
>
> Editorial Board 2002-present Molecular Cancer Therapeutics
>
> Editorial Board 2004-present Current Cancer Therapy Reviews
>
> Editorial Board 2005-present Journal American Pharmacists Association
>
> Editorial Board 2005-present Recent Patents on Anti-Cancer Drug
> Discovery
>
> Editorial Board 2006-present Clinical Genitourinary Cancer
>
> Editorial Board 2007-present The Open Cancer Letters
>
> Reviewer: Journal of Chromatograph B Pharmacogenetics
>
> Investigational New Drugs Antimicrobial Agents and Chemotherapy
>
> Southern Medical Journal American Journal Pathology
>
> Biochemical Pharmacology Cancer Research
>
> Annals of Pharmacotherapy Journal of Oncology Pharmacy Practice
>
> Cancer Investigation Journal American Medical Association
>
> British Journal of Cancer J of Pharmacokinetic and Pharmacodynamics
>
> Cancer Journal of National Cancer Institute
>
> Analytica Chimica Acta Journal Clinical Investigation
>
> Lipids American Hospital Formulary Service
>
> Biotechniques Molecular Medicine Today
>
> Blood Trends in Pharmacology Science
>
> Molecular Pharmacology Human Genetics
>
> Clin Pharmacology Therapeutics Cancer Chemotherapy Pharmacology
>
> FASEB Letters Nature Cancer Review
>
> Journal of Urology The Oncologist
>
> Journal of Molecular Medicine Urology
>
> J Pharmacology Exp Therapeutics Laboratory Investigation
>
> The Pharmacogenomic Journal Cancer Epidemiology, Biomarkers and
> Prevention
>
> Biol of Blood Marrow Transpl Journal of Clinical Oncology
>
> European Journal of Cancer Journal of Pharmacy and Pharmacology
>
> Neoplasia In Vitro Cellular and Developmental Biology
>
> Journal of Pathology British Journal Hematology
>
> Proc Natl Academy Science European Urology
>
> Oncogene Leukemia
>
> Human Mutation Life Sciences
>
> Lancet Bioorganic & Medicinal Chemistry
>
> **University Organizations/Activities:**
>
> Golf Team - Georgetown College, 1982
>
> Kappa Alpha - Georgetown College, 1982
>
> Phi Delta Chi - Samford University, 1984
>
> **Awards, Honors and Fellowships:**
>
> Beta Beta Beta, Samford University, 1985
>
> Outstanding Young Men of America, 1987
>
> Glaxo Research Institute Fellowship, 1990-92
>
> Recipient NIH Research Award - Student Loan Repayment, 1992-93
>
> Who's Who in the East, 1998, 1999, 2000
>
> Who's Who in America, 2000
>
> 1996 McKeen Cattell Award from American College of Clinical
> Pharmacology's
>
> Journal of Clinical Pharmacology (co-author)
>
> 1997 Fellow, American College of Clinical Pharmacy
>
> 2000 Fellow, American College of Clinical Pharmacology
>
> 2001 Allen J. Brands Clinical Pharmacist of the Year Award,
>
> US Public Health Service Commissioned Officers Association
>
> 2003 Association of Military Surgeons of the United States,
>
> Clinical Pharmacist of the Year Award
>
> 2003 Center for Cancer Research Federal Technology Transfer Award
>
> 2004 Ohio County High School, Hartford, KY -- Alumni Professional
> Achievement Award
>
> 2003 US Navy, Meritorious Unit Commendation
>
> 2004 Academy of Medicine, Washington, DC -- elected member
>
> 2004 Center for Cancer Research Federal Technology Transfer Award
>
> 2005 Leon I. Goldberg Young Investigator Award,
>
> American Society of Clinical Pharmacology and Therapeutics
>
> 2005 19^th^ Annual Singapore World Pharmacy Congress, Keynote Lecture
> and Award
>
> 2005 Center for Cancer Research Federal Technology Transfer Award
>
> 2006 Center for Cancer Research Federal Technology Transfer Award
>
> 2007 Center for Cancer Research Federal Technology Transfer Award
>
> 2007 The Annual Graduate Student Invited Lecture, Dartmouth College of
> Medicine, Department of
>
> Pharmacology and Toxicology
>
> 2007 NVCA Teacher of the Year Award
>
> 2007 NIH Clinical Center Director's Award
>
> 2008 Columbia University Business School Non-Profit Alumni Award
>
> 2008 Samford University School of Pharmacy -- Commencement Address
>
> 2008 Russell R. Miller Award, American College of Clinical Pharmacy
>
> **Executive Management Training:**
>
> Johns Hopkins University, School of Business, Baltimore, MD,
>
> Leadership and Organizational Behavior, 1994
>
> Wharton School of Management, University of Pennsylvania,
> Philadelphia, PA,
>
> Essentials of Management, 1998, 1999
>
> **Certifications:**
>
> Basic Life Support (1989 -- present)
>
> **Bibliography:**

1.  Avent CK, Krinsky D, Kirklin JK, Bourge RC, **Figg WD**. Synergistic
    Nephrotoxicity Due to Ciprofloxacin and Cyclosporine. *Am J Med*
    1988;85:452-3.

2.  **Figg WD**. Cyclosporine-Induced Hyperuricemia and Gout. *N Engl J
    Med* (letter) 1990;322:334-5.

3.  Thompson G, **Figg WD**. Diarrhea Precipitated by Oral Liquid
    Medication. *Am J Med* (letter) 1990;89:697.

4.  Bourge RC, Kirklin JK, Naftel DC, **Figg WD**, Williams-White C,
    Ketchum C. Diltiazem-Cyclosporine Interaction in Cardiac Transplant
    Patients: Impact on Cyclosporine Dose and Medication Costs. *Am J
    Med* 1991;90:402-4.

5.  **Figg WD**. Peripheral Neuropathy in HIV Patient after Isoniazid
    Therapy Initiated. *Annals of Pharmacotherapy* (letter)
    1991;25:100-1.

6.  **Figg WD**. Aseptic Meningitis Associated with Muromonab-CD3.
    *Annals of Pharmacotherapy* (letter) 1991;25:1395.

7.  **Figg WD**. Ondansetron versus Dexamethasone. *Lancet* (letter)
    1991;338:946.

8.  Thibault A, **Figg WD**, Cooper MR, Prindiville SA, Sartor AO,
    Headlee DJ, Myers CE. Anaphylactoid Reaction with Suramin.
    *Pharmacotherapy* 1993;13:656-7.

9.  Erratum: Annalphylactoid Reaction with Suram. *Pharmacotherapy*
    1994;14:125.

10. **Figg WD**, Thibault A. Book Review: Oxford Textbook of Clinical
    Pharmacology and Drug Therapy. *Annals of Pharmacotherapy*
    1993;27:797.

11. **Figg WD**, Graham CL, Hak LJ, Dukes GE. Ondansetron: A Novel
    Antiemetic Agent. *S Med J* 1993;86:497-502.

12. Thibault A, **Figg WD**. Book Review: Cancer of the Prostate. *J
    Natl Cancer Inst* 1993;85:1958-9.

13. Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A,
    Steinberg S, **Figg WD**, Linehan WM, Myers CE. Surprising Activity
    of Flutamide Withdrawal, When Combined with Aminoglutethimide, in
    Treatment of "Hormone-Refractory" Prostate Cancer. *J Natl Cancer
    Inst* 1994;86:222-7.

14. **Figg WD**, Yeh HJC, Thibault A, Pluda JM, Itoh F, Yarchoan R,
    Cooper MR. Assay of the AntiangiogenicCompound, TNP-470, and One of
    its Metabolites, AGM-1883, by Reversed-Phase High Performance Liquid
    Chromatography in Plasma. *J Chrom B* 1994;652:187-94.

15. Thibault A, Cooper MR, **Figg WD**, Venzon DJ, Sartor AO, Tompkins
    AC, Weinberger MS, Headlee DJ, McCall NA, Samid D, Myers CE. A Phase
    I and Pharmacokinetic Study of Intravenous Phenylacetate in Patients
    with Cancer. *Cancer Res* 1994;54:1690-4.

16. Thibault A, **Figg WD**, McCall NA, Samid D, Myers CE, Cooper MR. A
    Simultaneous Assay of the Differentiating Agents, Phenylacetic Acid
    and Phenylbutyric Acid, and One of Their Metabolites,
    Phenylacetylglutamine, by Reversed-Phase, High Performance Liquid
    Chromatography. *J Liq Chrom* 1994;17:2895-900.

17. **Figg WD**, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA,
    Cooper MR. Hypothyroidism Associated with Aminoglutethimide in
    Patients with Prostate Cancer. *Arch Int Med* 1994;154:1023-5.

18. **Figg WD**, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA,
    Myers CE, Samid D. *In Vitro* Antitumor Effect of Hydroxyurea on
    Hormone-Refractory Prostate Cancer Cells and its Potentiation by
    Phenylbutyrate. *Anti-Cancer Drugs* 1994;5:336-42.

19. **Figg WD**, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan
    RC, Reed E, Sartor O. Acute Renal Toxicity Associated with Suramin
    in the Treatment of Prostate Cancer. *Cancer* 1994;74:1612-4.

20. Foss FM, Borkowski TA, Gilliom M, Stetler-Stevenson MA, Jaffe ES,
    **Figg WD**, Tompkins A, Bastian A, Nylen P, Woodworth T, Udey MC,
    Sausville EA. Chimeric Fusion Protein Toxin DAB486IL-2 in Advanced
    Mycosis Fungoides and the Sezary Syndrome: Correlation of Activity
    and Interleukin-2 Receptor Expression in a Phase II Study. *Blood*
    1994;84:1765-74.

21. **Figg WD**, Stevens JA, Cooper MR. Adaptive Control With Feedback
    of Suramin Using Intermittent Infusions. *J Clin Oncol* (letter)
    1994;12:1523-4.

22. **Figg WD**. Angiogenesis: A Therapeutic Target for Tumor
    Suppression. *Issues in Pharmacotherapy* 1994;14:3.

23. **Figg WD**, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N,
    Reed E, Myers CE. Prostate Specific Antigen Decline Following the
    Discontinuation of Flutamide in Patients with Stage D2 Prostate
    Cancer. *Am J Med* 1995;98:412-4.

24. **Figg WD**, Dukes GE, Lesesne HR, Carson SW, Songer SS, Pritchard
    JF, Hermann DJ, Powell JR, Hak LJ. Comparison of Quantitative
    Methods to Assess Hepatic Function: Pugh's Classification,
    Indocyanine Green, Antipyrine, and Dextromethorphan.
    *Pharmacotherapy* 1995;15:693-700.

25. Thibault A, Samid D, Cooper MR, **Figg WD**, Tompkins AC, Patronas
    N, Headlee DJ, Kohler DR, Venzon DJ, Myers CE. Phase I Study of
    Phenylacetate Administered Twice Daily to Patients with Cancer.
    *Cancer* 1995;75:2932-8.

26. Piscitelli SC, Thibault A, **Figg WD**, Tompkins A, Headlee D,
    Lieberman R, Samid D, Myers CE. Disposition of Phenylbutyrate and
    its Metabolites, Phenylacetate and Phenylacetylglutamine. *J
    Clinical Pharmacology* 1995;35:368-73.

27. **Figg WD**, McCall NA, Reed E, Sartor O. The *in vitro* Response of
    Four Antisteroid Receptor Agents on the Hormone-Responsive Prostate
    Cancer Cell Line LNCaP. *Oncol Report* 1995;2:295-8.

28. Bitton RJ, **Figg WD**, Venzon DJ, Dalakas MC, Bowden C, Headlee D,
    Reed E, Myers CE, Cooper MR. Pharmacologic Variables Associated with
    the Development of Neurologic Toxicity in Patients Treated with
    Suramin. *J Clin Oncol* 1995;13:2223-9.

29. **Figg WD**, Middleman MN, Sartor O. Mutated Androgen Receptors of
    Prostate-Cancer Cells. *N Engl J Med* (letter) 1995;333:1010.

30. **Figg WD**, Thibault A, Cooper MR, Reid B, Headlee D, Dawson N,
    Kohler DR, Reed E, Sartor O. A Phase I Study of the Somatostatin
    Analogue Somatuline in Patients with Metastatic Hormone-Refractory
    Prostate Cancer. *Cancer* 1995;75:2159-64.

31. McCall NA, Samid D, **Figg WD**. Stability of Sodium Phenylacetate
    and Sodium Phenylbutyrate in Parenteral Large-Volume Sterile Water.
    *Drug Stability* 1995;1:54-8.

32. Danesi R, **Figg WD**, Reed E, Myers CE. Paclitaxel (Taxol®)
    Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human
    Prostate Cancer Cells. *Mol Pharmacol* 1995;47:1106-11.

33. Sausville EA, Headlee D, Stetler-Stevenson M, Jaffe ES, Solomon D,
    **Figg WD**, Herdt J, Kopp WC, Rager H, Steinberg SM, Ghetie V,
    Schindler J, Uhr J, Wittes RE, Vitetta ES. Continuous Infusion of
    the Anti-CD22 Immunotoxin IgG-RFB4-SMPT-dgA in Patients with B-Cell
    Lymphoma: A Phase I Study. *Blood* 1995;85:3457-65.

34. **Figg WD**, Cole KA, Reed E, Steinberg SM, Piscitelli SC, Davis PA,
    Soltis MJ, Jacob J, Boudoulas S, Goldspiel B, Sarosy G, Liotta LA,
    Kohn EC. Pharmacokinetics of Orally Administered
    Carboxyamido-triazole, an Inhibitor of Calcium-mediated Signal
    Transduction. *Clin Cancer Res* 1995;1:797-803.

35. Dawson NA, Cooper MR, **Figg WD**, Headlee DJ, Thibault A, Bergan
    RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Antitumor
    Activity of Suramin in Hormone-Refractory Prostate Cancer
    Controlling for Hydrocortisone Treatment and Flutamide Withdrawal as
    Potentially Confounding Variables. *Cancer* 1995;76:453-62.

36. Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Prolonged
    Response to Flutamide Withdrawal and Initiation of Aminoglutethimide
    in a Patient with Metastatic Prostate Cancer. *J Oncol Pharm
    Practice* 1995;1:45-7.

37. Guetta V, Lush RM, **Figg WD**, Waclawiw MA, Cannon RO. Effects of
    the Antiestrogen Tamoxifen on Low-Density Lipoprotein Concentrations
    and Oxidation in Postmenopausal Women. *Am J Cardiology*
    1995;76:1072-3.

38. Bitton RJ, **Figg WD**, Reed E. A Preliminary Risk-Benefit
    Assessment of Paclitaxel. *Drug Safety* 1995;12:196-208.

39. Bowden CJ, **Figg WD**, Dawson NA, Sartor O, Bitton RJ, Weinberger
    MS, Headlee D, Reed E, Myers CE, Cooper MR. A Phase I/II Study of
    Continuous Infusion Suramin in Patients with Hormone-Refractory
    Prostate Cancer: Toxicity and Response. *Cancer Chemother
    Pharmacology* 1996;39:1-8.

40. Sartor O, **Figg WD**. Mifepristone: Antineoplastic Studies. In
    Pitkin RM, Scott JR (Editors) [Clinical Obstetrics and
    Gynecology.]{.underline} Published by Lippincott-Raven,
    Philadelphia, PA, 1996:498-505.

41. **Figg WD**, Middleman MN, Sartor O. Therapeutic Options in Patients
    with Hormone-Refractory Prostate Cancer. *American J Med* (letter)
    1996;100:243-4.

42. Tisdale JF, **Figg WD**, Reed E, McCall NA, Alkins BR, Horne MK.
    Severe Thrombocytopenia in Patients Treated with Suramin: Evidence
    for an Immune Mechanism in One. *Am J Hematol* 1996;51:152-7.

43. **Figg WD**, Ammerman K, Patronas N, Steinberg SM, Walls RG, Dawson
    N, Reed E, Sartor O. Lack of Correlation Between Prostate Specific
    Antigen and the Presence of Measurable Soft Tissue Metastases in
    Hormone-Refractory Prostate Cancer. *Cancer Invest* 1996:14:513-7.

44. Lush RM, Nguyen BY, Cundy KC, Bauza S, Sogocio T, Stevens J,
    Piscitelli S, Venzon D, Yarchoan R, **Figg WD**. Pharmacokinetics of
    (s)-9-(2-Phosphonylmethoxyethyl)adenine (PMEA) and when Administered
    in Combination with Zidovidine (AZT). *J Applied Ther* 1996;1:13-8.

45. Walls R, Thibault A, Lui L, Wood C, Kozlowski JM, **Figg WD**,
    Sampson ML, Elin RJ, Samid D. The Differentiating Agent
    Phenylacetate Increases Prostate-Specific Antigen Production by
    Prostate Cancer Cells. *The Prostate* 1996;29:177-82.

46. Walther MM, **Figg WD**, Linehan WM. Intravesical Suramin: A Novel
    Agent for the Treatment of Superficial Transitional-Cell Carcinoma
    of the Bladder. *World J Urol* 1996;14:S8-S11.

47. Middleman MN, Lush RM, **Figg WD**. The Mutated Androgen Receptor
    and Its Implications for the Treatment of Metastatic Carcinoma of
    the Prostate. *Pharmacotherapy* 1996;16:376-81.

48. Lush RM, **Figg WD**, Pluda JM, Bitton R, Headlee D, Kohler D, Reed
    E, Sartor O, Cooper MR. A Phase I Study of Pentosan Polysulfate
    Sodium in Patients with Advanced Malignancies. *Annals of Oncology*
    1996;7:939-44.

49. Middleman MN, Lush RM, Sartor O, Reed E, **Figg WD**. Treatment
    Approaches for Metastatic Cancer of the Prostate based on Recent
    Molecular Evidence. *Cancer Treatment Rev* 1996;22:105-18.

50. Kohn EC, Reed E, Sarosy G, Christian M, Link CJ, Cole K, **Figg
    WD**, Davis PA, Jacob J, Goldspiel B, Liotta L. Clinical
    Investigation of a Cytostatic Calcium Influx Inhibitor in Patients
    with Refractory Cancer. *Cancer Res* 1996;56:569-73.

51. Thibault A, Samid D, Tompkins AC, **Figg WD**, Cooper MR, Hohl RJ,
    Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE. Phase I
    Study of Lovastatin, an Inhibitor of the Mevalonate Pathway, in
    Patients with Cancer. *Clin Cancer Res* 1996;2:483-91.

52. **Figg WD**, Dukes GE, Pritchard JF, Hermann DJ, Lesesne HR, Carson
    SW, Songer SS, Powell JR, Hak LJ. Pharmacokinetics of Ondansetron in
    Patients with Hepatic Insufficiency. *J Clinical Pharmacology*
    1996;36:206-15.

53. **Figg WD**, Dawson N, Middleman MN, Brawley O, Lush RM, Senderowicz
    A, Steinberg SM, Tompkins A, Reed E, Sartor O. Flutamide Withdrawal
    and Concomitant Initiation of Aminoglutethimide in Patients with
    Hormone Refractory Prostate Cancer. *Acta Oncol* 1996;35:763-5.

54. Boudoulas S, Lush RM, McCall NA, Samid D, Reed E, **Figg WD**.
    Plasma Protein Binding of Phenylacetate and Phenylbutyrate, Two
    Novel Antineoplastic Agents. *Ther Drug Monit* 1996;18:714-20.

55. Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, **Figg
    WD**. Suramin-Induced Neutropenia. *Eur J Cancer* 1996;32A:1534-9.

56. Stone MJ, Sausville EA, Fay JW, Headlee D, Collins RH, **Figg WD**,
    Stetler-Stevenson M, Jain V, Jaffe ES, Solomon D, Lush RM,
    Senderowicz A, Ghetie V, Schindler J, Uhr JW, Vitetta ES. A Phase I
    Study of Bolus vs. Continuous Infusion of the Anti-CD19 Immunotoxin,
    IgG-HD37-dgA in Patients with B Cell Lymphoma. *Blood*
    1996;88:1188-97.

57. Simmons BR, Bauer KS, McCall NA, Kohn EC, **Figg WD**. An optimized
    Method for the Quantitation of Carboxyamido-triazole (CAI) in Human
    Plasma with Solid Phase Extraction and Reverse Phase HPLC. *Analy
    Let* 1996;30:2009-21.

58. Lush RM, **Figg WD**. Book Review: Principles of Antineoplastic Drug
    Development and Pharmacology. *Annals Pharmacotherapy* 1997;31:377.

59. Dixon SC, Soriano BJ, Lush RM, Borner MM, **Figg WD**. Apoptosis:
    Its Role in the Development of Malignancies and Its Potential as a
    Novel Therapeutic Target. *Annals Pharmacotherapy* 1997;31:76-82.

60. Piscitelli SC, Reiss WG, **Figg WD**, Petros WP. Pharmacokinetic
    Studies with Recombinant Cytokines: Scientific Issues and Practical
    Considerations. *Clinical Pharmacokinetic* 1997;32:368-81.

61. **Figg WD**, Feuer J, Bauer KS. Management of Hormone-Sensitive
    Metastatic Prostate Cancer. *Cancer Practice* 1997;5:258-263.

62. Masiero L, **Figg WD**, Kohn EC. New Anti-angiogenesis Agents:
    Review of Experience with Carboxyaminido-triazole (CAI),
    Thalidomide, TNP-470, and interleukin-12. *The Angiogenesis J*
    1997;1:23-35.

63. **Figg WD**, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E,
    Yarchoan R. The Pharmacokinetics of TNP-470, A New Angiogenesis
    Inhibitor. *Pharmacotherapy* 1997;17:91-7.

64. Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, **Figg
    WD**. Initial Pharmacokinetics and Bioavailability of PSC 833, a
    P-Glycoprotein Antagonist. *J Clinical Pharmacology* 1997;37:123-8.

65. **Figg WD**, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy
    G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E.
    Pharmacokinetics of Elemental Platinum (Ultrafiltrate and Total)
    After a Thirty Minute Intravenous Infusion of Ormaplatin. *Biopharm
    Drug Disp* 1997;18:347-359.

66. Piscitelli SC, Forrest A, Lush RM, Ryan N, Whitfield LR, **Figg
    WD**. Pharmacometric Analysis of the Effect of Furosemide on Suramin
    Pharmacokinetics. *Pharmacotherapy* 1997;17:431-7.

67. Walsh TJ, Whitcomb T, Piscitelli S, **Figg WD**, Hill S, Chanock SJ,
    Jarosinski P, Gupta R, Pizzo PA. Safety, Tolerance, and
    Pharmacokinetics of Amphotericin B Lipid Complex in Children with
    Hepatosplenic Candidiasis. *Antimicrob Agents Chemother*
    1997;41:1944-8.

68. Senderowicz AM, Vitetta E, Headlee D, Ghetie V, Uhr JW, **Figg WD**,
    Lush RM, Stetler-Stevenson M, Kershaw G, Kingma DW, Jaffe E,
    Sausville EA. Complete Sustained Response of a Refractory
    Post-Transplantation, Large B-cell Lymphoma to an Anti-CD22
    Immunotoxin. *Annals Internal Med* 1997;126:882-5.

69. Bartlett DL, Buell JF, Libutti SK, Reed E, Lee KB, **Figg WD**,
    Venzon DJ, Alexander HR. A Phase I Trial of Continuous Hyperthermic
    Peritoneal Perfusion with Tumor Necrosis Factor and Cisplatin in the
    Treatment of Peritoneal Carcinomatosis. *Cancer* 1998;83:1251-61. Ma
    GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti SK,
    Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with
    Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J
    Sci Am* 1997;3:174-9.

70. Ma GY, Bartlett DL, Reed E, **Figg WD**, Lush RM, Lee KB, Libutti
    SK, Alexander HR. Continuous Hyperthermic Peritoneal Perfusion with
    Cisplatin for the Treatment of Peritoneal Mesothelioma. *Cancer J
    Sci Am* 1997;3:174-9.

71. Simmons BR, Lush RM, **Figg WD**. A Reversed-Phase high performance
    liquid chromatography method using Solid Phase Extraction to
    Quantitate Thalidomide in Human Serum. *Analy Chim Acta*
    1997;339:91-7.

72. Bergan RC, Walls R, **Figg WD**, Dawson NA, Headlee D, Tompkins A,
    Steinberg SM, Reed E. Similar Clinical Outcomes in African American
    and non-African American Males Treated with Suramin for Metastatic
    Prostate Cancer. *J Natl Med Assoc* 1997;89:622-8.

73. Dawson NA, **Figg WD**, Cooper MR, Sartor O, Bergan RC, Senderowicz
    A, Steinberg SM, Tompkins A, Weinberger BM, Sausville EA, Reed E,
    Myers CE. A Phase II Trial of Suramin, Leuprolide, and Flutamide in
    Previously Untreated Metastatic Prostate Cancer. *J Clin Oncol*
    1997;15:1470-7.

74. **Figg WD**, Kroog G, Duray P, Walther MM, Patronas N, Sartor O,
    Reed E. Flutamide Withdrawal Plus Hydrocortisone Resulted in
    Clinical Complete Response in a Patient with Prostate Carcinoma.
    *Cancer* 1997;79:1964-8.

75. Dixon S, Zalles A, Giordano C, Venzon D, Lush RM, Reed E, **Figg
    WD**. In vitro Effect of Gallium Nitrate when combined with
    Ketoconazole in the Prostate Cancer Cell Line PC-3. *Cancer Letter*
    1997;113:111-6.

76. Kohn EC, **Figg WD**, Sarosy GA, Bauer KS, Davis PA, Soltis MJ,
    Tompkins A, Liotta LA, Reed E. Phase I Trial of Micronized
    Formulation Carboxyamidotriazole in Patients with Refractory Solid
    Tumors: Pharmacokinetics, Clinical Outcome and Comparison of
    Formulations. *J Clinical Oncology* 1997;15:1985-93.

77. Piscitelli SC, **Figg WD**, Hahn B, Kelly G, Thomas S, Walker RE.
    Single-Dose Pharmacokinetics of Thalidomide in Human
    Immunodeficiency Virus-Infected Patients. *Antimicrob Agents
    Chemother* 1997;41:2797-9.

78. Dawson N, **Figg WD**, Brawley O, Bergan RC, Cooper MR, Senderowicz
    AM, Headlee D, Steinberg SM, Sutherland M, Patronas N, Sausville E,
    Linehan M, Reed E, Sartor O. A Phase II Study of Suramin Plus
    Aminoglutethimide in Two Cohorts of Patients with
    Androgen-Independent Prostate Cancer: Simultaneous Antiandrogen
    Withdrawal and Prior Antiandrogen Withdrawal. *Clin Cancer Res*
    1998;4:37-44.

79. Welles L, Saville MW, Lietzau J, Pluda JM, Wyvill KM, Feuerstein I,
    **Figg WD**, Lush R, Odom J, Wilson WH, Fajardo MT, Humphrey RW,
    Feigal E, Tuck D, Steinberg SM, Broder S, Yarchoan R. Phase II Trial
    with Dose Titration of Paclitaxel for the Therapy of Human
    Immunodeficiency Virus-Associated Kaposi's Sarcoma. *J Clinical
    Oncology* 1998;16:1112-21.

80. Thibault A, **Figg WD**, Bergan RC, Lush RM, Myers CE, Tompkins A,
    Reed E, Samid D. A Phase II Study of 5-Aza-2'-Deoxycytidine
    (Decitabine) in Hormone Independent Metastatic (D2) Prostate Cancer.
    *Tumori* 1998;84:87-9.

81. Sartor O, Weinberger M, Moore A, Li A, **Figg WD**. Effect of
    Prednisone on Prostate-Specific Antigen in Patients with Hormone
    Refractory Progressive Prostate Cancer. *Urology* 1998;52:252-6.

82. Feuer JA, Lush RM, Venzon D, Duray P, Tompkins A, Sartor O, **Figg
    WD**. Elevated Carcinomembryonic Antigen in Patients with
    androgen-independent Prostate Cancer. *J Invest Med* 1998;46:66-72.

83. Bauer KS, Dixon SC, **Figg WD**. Inhibition of Angiogenesis by
    Thalidomide Requires Metabolic Activation which is
    Species-Dependent. *Biochem Pharmacology* 1998;55:1827-34.

84. Horti J, **Figg WD**, Weinberger B, Kohler D, Sartor O. A Phase II
    Study of Bromocriptine in Patients with Androgen Independent
    Prostate Cancer. *Oncology Report* 1998;5:893-6.

85. Dixon SC, Horti J, Guo Y, Reed E, **Figg WD**. Methods for
    Extracting and Amplifying Genomic DNA isolated from Frozen Serum.
    *Nature Biotechnol* 1998;16:91-4.

86. Alexander HR, Brown CK, Bartlett DL, Libutti SK, **Figg WD**, Raje
    S, Turner E. Augmented Capillary Leak During Isolated Hepatic
    Perfusion (IHP) Occurs Via Tumor Necrosis Factor Independent
    Mechanisms. *Clin Cancer Res* 1998;4:2357-62.

87. Sausville EA, Lush RM, Headlee D, Smith AC, **Figg WD**, Arbuck SG,
    Senderowicz AM, Fuse E, Tanii H, Kuwabara T, Kobayashi S. Clinical
    Pharmacology of UCN-01: Initial Observations and Comparison to
    Preclinical Models. *Cancer Chemother Pharmacol*
    1998;42(Suppl)S54-9.

88. Piscitelli SC, Vogel S, **Figg WD**, Raje S, Forrest A, Metcalf JA,
    Baseler M, Falloon J. Alteration in Indinavir Clearance During
    Interleukin-2 Infusions in Patients Infected with the Human
    Immunodeficiency Virus. *Pharmacotherapy* 1998;18:1212-6.

89. **Figg WD**, Kim G. The Role of Angiogenesis Inhibition in
    Metastatic Prostate Cancer. *Adv Prostate Cancer* 1998;8:2-5.

90. Fuse E, Tannii H, Kurata N, Kobayashi H, Shimada Y, Tamura T, Sasaki
    Y, Tanigawara Y, Lush RM, Headlee D, **Figg WD**, Arbuck SG,
    Senderowicz AM, Sausville EA, Akinaga S, Kuwabara T, Kobayashi S.
    Unpredicted Clinical Pharmacology of UCN-01 Caused by Specific
    Binding to Human alpha1-acid glycoprotein. *Cancer Res*
    1998;58:3248-53.

91. Bauer KC, Lush RM, Rudek MA, **Figg WD**. Novel Targets in Cancer
    Therapy: Angiogenesis, Matrix Metalloproteinase, Cyclin-Dependent
    Kinases, and Signal Transduction. *Highlights in Oncology Pract*
    1998;16:3-11.

92. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L,
    Steinberg S, **Figg WD**, Tompkins A, Arbuck S, Sausville EA. A
    Phase I Trial of Continuous Infusion Flavopiridol, a Novel
    Cyclin-dependent Kinase Inhibitor, in Patients with Refractory
    Neoplasms. *J Clin Oncol* 1998;16:2986-99.

93. Bauer KS, Kohn EC, Lush RM, Steinberg SM, Davis P, Kohler D, Reed E,
    **Figg WD**. Pharmacokinetics and Relative Bioavailability of
    Carboxyamido-triazole with Respect to Food and Time of
    Administration: Use of a Single Model for Simultaneous Determination
    of Changing Parameters. *J Pharmacokin Biopharm* 1998;26:673-87.

94. Arah IN, Dixon SC, Horti J, **Figg WD**. Enhanced Activity of
    Estramustine, Vinblastine, Etoposide and Suramin in Prostate
    Carcinoma. *Neoplasma* 1999;46:117-23.

95. **Figg WD**, Pluda JM, Sartor O. Pentosan Polysulfate: A
    Polysaccharide that Inhibits Angiogenesis by Binding Growth Factors.
    In Teicher BA (Editor) [Antiangiogenic Agents in Cancer
    Therapy]{.underline}. Published by Humana Press, Inc., Totowa, NJ,
    1999;371-383.

96. Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, **Figg WD**.
    Increased Transcriptional Activity of Prostate Specific Antigen in
    the Presence of TNP-470, An Angiogenesis Inhibitor. *Br J Cancer*
    1999;79:1588-93.

97. **Figg WD**, Reed E, Green S, Pluda JM. Thalidomide, A Prodrug
    Inhibits Angiogenesis. In Teicher BA (Editor) [Antiangiogenic Agents
    in Cancer Therapy]{.underline}. Published by Humana Press, Inc.,
    Totowa, NY, 1999;407-22.

98. Kang MH, **Figg WD**, Dahut W. Taxanes in Hormone Refractory
    Prostate Cancer. *Cancer Pract* 1999;7:270-2.

99. Buckner JC, Malkin MG, Reed E, Cascino TL, Reid JM, Ames MM, Tong
    WPY, Lim S, **Figg WD**. Phase II Study of Antineoplastons A10
    (NSC 648539) and AS2-1 (NSC 620261) in Patients with Recurrent
    Glioma. *Mayo Clin Proc* 1999;74:137-45.

100. Lush RM, Rudek MA, **Figg WD**. Review of Three New Agents that
     Target Angiogenesis, Matrix Metalloproteinases and Cyclin Dependent
     Kinases. *Cancer Control* 1999;6:459-465.

101. Melchior SW, Brown LG, **Figg WD**, Quinn JE, Santucci RA, Brunner
     J, Thuroff JW, Lange PH, Vessella RL. Effects of Phenylbutyrate on
     Proliferation and Apoptosis in Human Prostate Cancer Cells in vitro
     and in vivo. *Int J Oncology* 1999;14:501-8.

102. Bergan RC, Reed E, Myers CE, Headlee D, Brawley O, Cho HK, **Figg
     WD**, Tompkins A, Linehan WM, Kohler D, Steinberg SM,
     Blagosklonny MV. A Phase II Study of High Dose Tamoxifen in
     Patients with Hormone-Refractory Prostate Cancer. *Clin Cancer Res*
     1999;5:2366-73.

103. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, **Figg WD**.
     Therapy for Advanced Prostate Cancer with Granulocyte Macrophage
     Colony - Stimulating Factor. *Clin Cancer Res* 1999;5:1738-44.

104. Sartor O, **Figg WD**. Current Management of Hormone Refractory
     Prostate Cancer. In Woods DP, Honn KV (Editors) [The Oncobiology of
     the Prostate, Vol. 3]{.underline}. Published by JAI Press, Inc.,
     Stamford, CT, 1999;235-256.

105. Senderowicz AM, Reid R, Headlee D, Abornathy T, Horti J, Lush RM,
     Reed E, **Figg WD**, Sausville E. A Phase II Trial of Gallium
     Nitrate in Patients with Androgen Metastatic Prostate Cancer. *Urol
     Int* 1999;63:120-5.

106. **Figg WD**, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen
     A, Hamilton M, Pluda J, Reed E. Pharmacokinetics of Thalidomide in
     an Elderly Prostate Cancer Population. *J Pharm Sci* 1999;88:121-5.

107. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, Lee
     KB, Venzon DJ, Bauer KS, Reed E, **Figg WD**. Pharmacokinetics of
     Cisplatin Administered by Continuous Hyperthermic Peritoneal
     Perfusion (CHPP) to Patients with Peritoneal Carcinomatosis. *J
     Clin Pharmacol* 1999;39:394-401.

108. Reed E, Matthews D, Dyer V, **Figg WD**. Meningeal Carcinomatosis
     in Metastatic Prostate Cancer: A Case Report. *The Prostate J*
     1999;1:99-102.

109. **Figg WD**, Blumenfeld JR. Are We Making an Impact on Prostate
     Cancer? *Prostate Cancer and Prostatic Dis* 1999;2:60-61.

110. Dixon SC, Kruger EA, Bauer KS, **Figg WD**. Thalidomide Upregulates
     Prostate-Specific Antigen Secretion from LNCaP Cells. *Cancer
     Chemotherap Pharmacol* 1999;43:S78-84.

111. Sartor O, Rayford W, **Figg WD**. Management of Metastatic Prostate
     Cancer. In McConnell JD, Scardino PT (Editors) [Atlas of Clinical
     Urology, Vol. II. The Prostate]{.underline}. Published by Current
     Medicine, Inc., Philadelphia, PA, 1999;15.1-15.14.

112. Park BJ, Brown CK, Hu Y, Alexander HR, Horti J, Raje S, **Figg
     WD**, Bartlett DL. Augmentation of Melanoma-Specific Gene
     Expression using a Tandem Melanocyte-specific Enhancer Results in
     Increased Cytotoxicity of the Purine Nucleoside Phosphorylase Gene
     in Melanoma. *Human Gene Therapy* 1999;10:889-98.

113. Cude KJ, Dixon SC, Guo Y, Lisella J, **Figg WD**. The Androgen
     Receptor: Genetic Considerations in the Development and Treatment
     of Prostate Cancer. *J Mol Medicine* 1999;77:419-26.

114. Luzzio FA, Piatt Zacherl D, **Figg WD**. A Facile Scheme for
     Phthalimide/Phthalimidine Conversion. *Tetrahedron Letters*
     1999;40:2087-90.

115. Bauer KS, **Figg WD**, Hamilton JM, Jones EC, Premkumar A,
     Steinberg SM, Dyer V, Linehan WM, Pluda J, Reed E. A
     Pharmacokinetically Guided Phase II Study of Carboxyamido-triazole
     (CAI) in Androgen Independent Prostate Cancer. *Clin Cancer Res*
     1999;5:2324-9.

116. Saif MW, **Figg WD**, Hewitt S, Brosky K, Reed E, Dahut W.
     Malignant Ascites as Only Manifestation of Metastatic Prostate
     Cancer. *Prostate Cancer Prostat Dis* 1999;2:290-3.

117. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M,
     **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R,
     Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H,
     Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R,
     Wilding G. Eligibility and Response Guidelines for Phase II
     Clinical Trials in Androgen Independent Prostate Cancer:
     Recommendations from the Prostate-Specific Antigen Working Group.
     *J Clin Oncol* 1999;17:3461-7.

118. Erratum: Eligibility and Response Guidelines for Phase II Clinical
     Trials in Androgen Independent Prostate Cancer: Recommendations
     from the Prostate-Specific Antigen Working Group. *J Clin Oncol*
     2000;18:2644. Erratum: *J Clin Oncol* 2007;25:1154.

119. Kruger EA, Blagosklonny MV, Dixon SC, **Figg WD**. UCN-01, a
     Protein Kinase C Inhibitor, Inhibits Endothelial Cell Proliferation
     and Angiogenic Hypoxic Response. *Invasion Met* 2000;18:209-18.

120. Wilson WH, Sorbara L, **Figg WD**, Mont EK, Sausville E, Warren KE,
     Balis FM, Bauer K, Raffeld M, Senderowitz A, Monks A. Modulation of
     Clinical Drug Resistance in a B-Cell Lymphoma Patient by the
     Protein Kinase Inhibitor 7-Hydroxystaurosporine: Presentation of a
     Novel Therapeutic Paradigm. *Clin Cancer Res* 2000;6:415-21.

121. Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, **Figg, WD**. A
     High-Performance Liquid Chromatography Method using Ultraviolet and
     Fluorescence Detection for the Quantitation of UCN-01,
     7-hydroxystaurosporine, from Human Plasma and Saliva. *Biomed
     Chromatogr* 2000;14:338-43.

122. Bauer KS, Cude KJ, Dixon SC, Kruger EA, **Figg WD**.
     Carboxyamido-Triazole Inhibits Angiogenesis by Blocking the
     Calcium-Mediated Nitric-Oxide Synthase-Vascular Endothelial Growth
     Factor Pathway. *J Pharmacol Exp Ther* 2000;292;31-7.

123. Kruger EA, Reed E, **Figg WD**. Thalidomide. In Rubanyi GM (Editor)
     [Angiogenesis in Health and Disease]{.underline}. Published by
     Marcel Dekker Inc., New York, NY, 2000;359-376.

124. Blagosklonny MV, Dixon SC, **Figg WD**. Efficacy of
     Microtubule-active Drugs followed by Ketoconazole in Human
     Metastatic Prostate Cancer Cell Lines. *J Urol* 2000;163:1022-6.

125. Luzzio FA, Thomas EM, **Figg WD**. Thalidomide metabolites and
     analogs. Part II: Cyclic derivatives of 2-N-phthalimido-2S,3S
     (3-hydroxy) ornithine. *Tetrahedron Letters* 2000;41:7151-5.

126. Fine HA, **Figg WD**, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS,
     Levin VA, Black PM, Kaplan R, Pluda JM, Yung WKA. A Phase II Trial
     of the Anti-angiogenic Agent Thalidomide in Patients with Recurrent
     High Grade Gliomas. *J Clin Oncol* 2000;18:708-15.

127. Luzzio FA, Mayorov AV, **Figg WD**. Thalidomide Metabolites I:
     Derivatives of (+)-2-(N-Phthalimido)-gamma-hydroxyglutamic acid.
     *Tetrahedron Letters* 2000,41,2275-2278.

128. Kruger EA, Duray PH, Tsokos MG, Libutti S, Dixon SC, Rudek M, Pluda
     J, Allegra C, **Figg WD**. Endostatin Inhibits Microvessel
     Formation in the *ex vivo* Rat Aortic Ring Angiogenesis Assay.
     *Biochem Biophys Res Comm* 2000;268:183-91.

129. Rudek MA, March CL, Bauer KS, Pluda JM **Figg WD**.
     High-Performance Liquid Chromatography with Mass Spectrometry
     Dection for Quantitating COL-3, A Chemically modified Tetracycline,
     in Human plasma in Human. *J Pharmaceut Biomed Anal*
     2000;22:1003-14.

130. Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, **Figg WD**.
     Newcomb FM, Tosato G, Feigal E, Steinberg SM, Whitby D, Goedert JJ,
     Yarchoan R. Activity of Thalidomide in AIDS-related Kaposi's
     Sarcoma. *J Clin Oncol* 2000;18:2593-602.

131. Berger AC, Alexander HR, Tang G, Wu PS, Hewitt SM, Turner E, Kruger
     E, **Figg WD**, Grove A, Kohn E, Stern D, Libutti SK. Endothelial
     Monocyte Activating Polypeptide II induces Endothelial Cell
     Apoptosis and May Inhibit Tumor Angiogenesis. *Microvascular Res*
     2000;60:70-80.

132. Berger AC, Feldman AL, Gnant MFX, Kruger EA, Sim BKL, **Figg WD**,
     Alexander HR, Libutti SK. The Angiogenesis Inhibitor, Endostatin
     Does Not Effect Murine Cutaneous Wound Healing. *J Surg Res*
     2000;91:26-31.

133. Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, **Figg WD**,
     Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe
     E, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA. A Phase I
     study of combination therapy with immunotoxin IgG
     HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox)
     in patients with refractory CD19(+), CD22(+) B cell lymphoma. *Clin
     Cancer Res* 2000:6:1302-13.

134. Kruger E, **Figg WD**. TNP-470: An Angiogenesis Inhibitor in
     Clinical Development for Cancer. *Exp Opin Investig Drugs*
     2000;9:1383-1396.

135. Woo EW, Quinn M, **Figg WD**, Dahut W. The Use of Complementary and
     Alternative Medicine in Prostate Cancer Patients. *Oncol Issues*
     2000;15:23-27.

136. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W,
     Demetri G, **Figg WD**, Zhou XP, Eng C, Spiegelman BM, Kantoff PW.
     Effects of Ligand Activation of peroxisome proliferators activated
     receptor γ on Human Prostate Cancer. *Proc Natl Acad Sci USA*
     2000;97:10990-5.

137. Montgomery JS, **Figg WD**. The Essential Role of Apoptosis in
     Prostate Cancer Therapy. *Highlights in Oncol Pract* 2000:18:64-71.

138. Salnikow K, Costa M, **Figg WD**, Blagosklonny MV.
     Hyperinducibility of Hypoxia-Responsive Genes without
     p53/p21-dependent Checkpoint in Aggressive Prostate Cancer. *Cancer
     Res* 2000;60:5630-4.

139. Thrasher JB, Deeths J, Bennett C, Iyer P, Dineen MK, Zhai S, **Figg
     WD**, McLeod DG. Comparative Study of the Clinical Efficacy of Two
     Dosing Regimens of Flutamide. *Mol Urol* 2000;4:259-63.

140. Walther MM, Rehak NN, Venzon D, Myers CE, Linehan WM, **Figg WD**.
     Suramin Administration is Associated with a Decrease in Serum
     Calcium Levels. *World J Urol* 2000;18:388-91.

141. Blagosklonny MV, Dixon SC, Robey R, **Figg WD**. Resistance to
     growth inhibitory and Apoptotic Effects of Phorbol Ester and UCN01
     in aggressive Cancer Cell Lines. *Int J Oncol* 2001;18:697-704.

142. Rochat B, Murray GI, **Figg WD**, McLeod HL. Human Cytochrome P450
     1B1 and Anticancer Agent Metabolism: Mechanism for Tumor Specific
     Drug Inactivation? *J Pharmacol Exper Therapeut* 2001;296:537-41.

143. Montgomery JS, Price DK, **Figg WD**. The Androgen Receptor Gene
     and its Influence on the Development and Progression of Prostate
     Cancer. *J Pathology* 2001:195:138-46.

144. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A,
     Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S,
     **Figg WD**, Fojo T, Bates S. A Phase I Study of Infusional
     Paclitaxel in Combination with the p-glycoprotein Antagonist
     PSC833. *J Clin Oncol* 2001;19:832-42.

145. Dixon SC, Knopf KB, **Figg WD**. The Control of Prostate Specific
     Antigen Expression and Gene Regulation by Pharmacological Agents.
     *Pharmacol Rev* 2001;53:73-91.

146. Logothetis CJ, Wu KK, Finn LD, Daliani D, **Figg W**, Ghaddar H,
     Gutterman JU. Phase I Trial of the Angiogenesis Inhibitor TNP-470
     for Progressive Androgen-independent Prostate Cancer. *Clin Cancer
     Res* 2001;7:1198-1203.

147. Bartlett DL, Libutti SK, **Figg WD**, Fraker DL, Alexander HR.
     Isolated Hepatic Perfusion for Unresectable Hepatic Metastases from
     Colorectal Cancer. *Surg* 2001;129:176-87.

148. Rudek MA, **Figg WD**, Dyer V, Dahut W, Turner ML, Steinberg SM,
     Liewehr DJ, Kohler DR, Pluda JM, Reed E. Phase I Clinical Trial of
     Oral COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with
     Refractory Metastatic Cancer. *J Clin Oncol* 2001;19:584-92.

149. Burstein AH, Reed E, Tompkins AC, Venzon D, **Figg WD**.
     Phenylacetate Pharmacokinetics Based on Interactive Two-Stage
     Population Analysis. *Pharmacotherap* 2001;21:281-6.

150. Ghate JV, Turner ML, Rudek MA, **Figg WD**, Dahut W, Dyer V, Pluda
     JM, Reed E. Drug-Induced Lupus Associated with COL-3: A report of 3
     cases. *Arch Dermatol* 2001;137:471-4.

151. **Figg WD**, Arlen P, Gulley J, Fernandez P, Noone M, Fedenko K,
     Hamilton M, Parker C, Kruger EA, Pluda J, Dahut WL. A randomized
     phase II trial of docetaxel (Taxotere) plus thalidomide in
     androgen-independent prostate cancer. *Semin Oncol* 2001;28(Suppl
     15):62-66.

152. Sunwoo JB, Herscher LL, Kroog GS, Thomas GR, Ondrey FG, Duffey DC,
     Solomon BI, Boss C, Albert PS, McCullugh L, Rudy S, Muir C, Zhai S,
     **Figg WD**, Cook JA, Mitchell JB, Van Waes C. Concurrent
     Paclitaxel and Radiation in the Treatment of Locally Advanced Head
     and Neck Cancer. *J Clin Oncol* 2001;19:800-11.

153. Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM,
     Murgo A, **Figg WD**, Lahusen T, Jaken S, Jing XX, Roberge M, Fuse
     E, Kuwabara T, Senderowicz AM. Phase I Trial of 72 hour Continuous
     Infusion UCN-01 in Patients with Refractory Neoplasms. *J Clin
     Oncol* 2001;19:2319-2333.

154. Dahut WD, Fedenko KM, Noone M, Arlen P, Gulley J, Pluda J, **Figg
     WD**. A Randomized Phase II Trial of Docetaxel plus Thalidomide in
     Androgen-Independent Prostate Cancer. *Adv Prostate Cancer*
     2001;5:8-10.

155. **Figg WD**, Dahut W, Duray P, Hamilton M, Tompkins A, Steinberg
     SM, Jones E, Premkumar A, Linehan WM, Floeter MK, Chen CC, Dixon
     SC, Kohler DR, Kruger E, Gubish E, Pluda JM, Reed E. A Randomized
     Phase II Trial of Thalidomide, An Angiogenesis Inhibitor, in
     Patients with Androgen Independent Prostate Cancer. *Clin Cancer
     Res* 2001;7:1888-93.

156. Woo EW, Messmann R, Sausville EA, **Figg WD**. Quantitative
     Determination of Perifosine, a Novel Alkylphosphocholine Anticancer
     Agent, in Human Plasma by Reversed-Phase Liquid Chromatography -
     Electrospray Mass Spectrometry. *J Chromatogr B* 2001;759:247-57.

157. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg
     SM, Dahut W, Pluda J, Kruger EA, Reed E, **Figg WD**. Thalidomide
     neuropathy in patients treated for metastatic prostate cancer.
     *Muscle Nerve* 2001;24;1050-7.

158. Rudek MA, Horne M, **Figg WD**, Dahut W, Dyer V, Pluda JM, Reed E.
     Reversible Sideroblastic Anemia Associated with the Tetracycline
     Analog COL-3. *Am J Hematol* 2001;67:51-3.

159. Kang MH, **Figg WD**, Ando Y, Blagosklonny MV, Liewehr D, Fojo T,
     Bates SE. The p-glycoprotein antagonist PSC 833 increases the
     Plasma concentrations of 6 alpha-hydroxypaclitaxel, a Major
     Metabolite of Paclitaxel. *Clin Cancer Res* 2001;7:1610-7.

160. Kohn EC, Reed E, Sarosy GA, Minasian L, Bauer KS, Bostick-Bruton F,
     Kulpa V, Fuse E, Tompkins A, Noone M, Goldspiel B, Pluda J, **Figg
     WD**, Liotta LA. A Phase I Trial of Carboxyamido-triazole and
     Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the
     Combination, and Demonstration of Pharmacokinetic Interaction.
     *Clin Cancer Res* 2001;7:1600-9.

161. Kruger EA, **Figg WD**. Protein Binding Alters the Activity of
     Suramin, Carboxyamidotriazole, and UCN-01 in an ex vivo Rat Aortic
     Ring Angiogenesis Assay. *Clin Cancer Res* 2001;7:1867-72.

162. Kruger EA, Duray PH, Price DK, Pluda JM, **Figg WD**. Approaches to
     Preclinical Screening Antiangiogenic Agents. *Sem Oncol*
     2001;28:570-576.

163. Bates S, Kang M, Meadows B, Bakke S, Meadows B, Choyke P, Merino M,
     Goldspiel B, Chico I, Smith T, Chen C, Robey R, Bergan R, **Figg
     WD**, Fojo T. A Phase I Study of Infusional Vinblastine in
     Combination with the Pgp Antagonist PSC 833 (Valdospar). *Cancer*
     2001;92:1577-1590.

164. Chang E, Alexander HR, Libutti SK, Hurst R, Zhai S, **Figg WD**.
     Bartlett DL. Laparoscopic Continuous Hyperthermic Peritoneal
     Perfusion. *J Am College of Surg* 2001;193:225-9

165. Gore SD, Weng LJ, Zhai S, **Figg WD**, Donehower RC, Dover GJ,
     Grever M, Griffin CA, Grochow LB, Rowinsky EK, Zabalena Y, Hawkins
     AL, Burks K, Miller CB. Impact of the Putative Differentiating
     Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute
     Myeloid Leukemia. *Clin Cancer Res* 2001;7:2330-9.

166. Carrasquillo JA, Whatley M, Dyer V, **Figg WD**, Dahut W.
     Alendronate does not interfere with 99m TC-methylene diphosphonate
     bone scanning. *J Nucl Med* 2001;42:1359-63.

167. Blagosklonny MV, Fojo T, Bhalla KN, Kim JS, Trepel JB, **Figg WD**,
     Rivera Y, Neckers L. The Hsp90 Inhibitor Geldanamycin Selectively
     Sensitizes Bcr-Abl-expressing Leukemia Cells to Cytotoxic
     Chemotherapy. *Leukemia* 2001;15:1537-43.

168. Gilbert J, Baker SD, Bowling MK, Grochow L, **Figg WD**, Zabelina
     Y, Donehower RC, Carducci MA. A Phase I Dose Escalation and
     Bioavailability Study of Oral Sodium Phenylbutyrate in Patients
     with Refractory Solid Tumor Malignancies. *Clin Cancer Res*
     2001;7:2292-2300.

169. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M,
     **Figg WD**, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R,
     Myers C, Oh W, Petrylak D, Reed E, Roth B, Sartor O, Scher H,
     Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R,
     Wilding G. Update: Eligibility and Response Guidelines for Phase II
     Clinical Trials in Androgen-Independent Prostate Cancer. *Classic
     Papers and Current Comments* 2001;6:311-7.

170. Schrump DS, Zhai S, Nguyen DM, Weiser TS, Fisher BA, Terrill RE,
     Flynn BM, Duray PH, **Figg WD**. Pharmacokinetics of Paclitaxel
     Administered by Hyperthermic Retrograde Isolated Lung Perfusion
     Techniques. *J Thorac and Cardiovascul Surg* 2002;123:686-694.

171. Arlen PM, **Figg WD**, Gulley J, Cox MC, Linehan WM, Dahut W.
     National Cancer Institute Intramural Approach to Advanced Prostate
     Cancer. *Clin Prostate Cancer* 2002;1:153-62.

172. Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L,
     Pluda JM, **Figg WD**, Krown SE, Dezube BJ. Matrix
     Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related
     Kaposi\'s Sarcoma: A Phase I AIDS Malignancy Consortium Study. *J
     Clin Oncol* 2002;20:153-159.

173. Bates SF, Chen C, Robey R, Kang M, **Figg WD**, Fojo T. Reversal of
     Multidrug Resistance: Lessons from Clinical Oncology. *Novartis
     Found Symp*. 2002;243:83-96; discussion 96-102, 180-5.

174. Kaur M, Reed E, Sartor O, Dahut W, **Figg WD**. Suramin\'s
     Development: What Did We Learn? *Invest New Drugs* 2002;20:209-219.

175. **Figg WD**, Kruger EA, Kim S, Price DK, and Dahut WD. Inhibition
     of Angiogenesis: Treatment Options for Patients with Metastatic
     Prostate Cancer. *Invest New Drugs* 2002;20:183-94.

176. Price DK, Ando Y, Kruger EA, Weiss M, **Figg WD**. 5\'-OH-
     Thalidomide, a Metabolite of Thalidomide, Inhibits Angiogenesis.
     *Therapeut Drug Monitoring* 2002;24:104-10.

177. Macpherson GR, Ng SS, Lakhani NJ, Price DK, Venitz J, **Figg WD**.
     Antiangiogenesis Therapeutic Strategies in Prostate Cancer. *Cancer
     Metastasis Rev* 2002;21:93-106.

178. Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF,
     Venzon D, Leiwher DJ, Johnson ME, Reed E, **Figg WD**. The Role of
     an Androgen Receptor Polymorphism in the Clinical Outcome of
     Patients with Metastatic Prostate Cancer. *Urol Int* 2002;68:16-23.

179. Ando Y, Fuse E, **Figg WD**. Thalidomide Metabolism by CYP2C
     subfamily. *Clin Cancer Res* 2002;8:1964-73.

180. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J,
     Brooks R, Piekarz RL, Tucker E, **Figg WD**, Chan KK, Goldspiel B,
     Fojo AT, Balcerzak SP, Bates SE. Phase I Trial of the Histone
     Deacetylase Inhibitor, Depsipeptide (FR901228, NSC 630176), in
     Patients with Refractory Neoplasms. *Clin Cancer Res*
     2002;8:718-28.

181. Zhai S, Senderowicz AM, Sausville EA, **Figg WD**. Flavopiridol, a
     Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development.
     *Annals Pharmacother* 2002;36:905-11.

182. Zhai S, Sausville E, **Figg WD**. A High Performance Liquid
     Chromatography Method Using Ultraviolet Detection for the
     Quantitation of Flavopiridol from Human Plasma. *Biomedical
     Chromatogr* 2002;16:379-82.

183. Gore SD, Weng LJ, **Figg WD**, Zhai S, Donehower RC, Dover G,
     Grever MR, Griffin C, Grochow LB, Hawkins A, Burks K, Zabelena Y,
     Miller CB. Impact of Prolonged Infusions of the Putative
     Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic
     Syndromes and Acute Myeloid Leukemia. *Clin Cancer Res*
     2002;8:963-970.

184. Neelapu S, **Figg WD**, Reed E. Leptomeningeal Carcinomatosis in
     Metastatic Prostate Cancer. *Southern Med J* 2002;95:107-8.

185. Beliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B,
     Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pepin
     MC, Courjal F, Ricard I, Poyet P, Falardeau P, **Figg WD**,
     Dupont E. The Antiangiogenic Agent Neovastat (AE-941) Inhibits
     Vascular Endothelial Growth Fractor-mediated Biological Effects.
     *Clin Cancer Res* 2002;8:1242-50.

186. Bennett CL, Price DK, Kim S, Liu D, Nathan D, Johnson ME,
     Montgomery JS, Cude K, Brockbank JC, Sartor O, **Figg WD**. Racial
     Variation in CAG repeat lengths within the Androgen Receptor gene
     among Prostate Cancer Patients of Lower Socioeconomic Status. *J
     Clin Oncol* 2002;20:3599-604.

187. Ando Y, **Figg WD**. Irinotecan in Small-Cell Lung Cancer. *New
     Engl J Med* (letter) 2002;346:1414-5.

188. Rudek MA, Venitz J, **Figg WD**. Matrix Metalloproteinase
     Inhibitors: Do they have a Place in the Anticancer Therapy?
     *Pharmacotherapy* 2002;22:705-720.

189. Ng SS, Brown M, **Figg WD**. Thalidomide, an Antiangiogenic Agent
     with Clinical Activity in Cancer. *Biomed Pharmacother*
     2002;56:194-9.

190. Gulley J, **Figg WD**, Dahut WD. Docetaxel plus Thalidomide in a
     Patient with Androgen-Independent Prostate Cancer: Case Report.
     *Case Studies in Prostate Cancer* 2002;3;1-7.

191. Liu Y, **Figg WD**. Antiangiogenesis: Does it Have a Role in the
     Treatment of Metastatic Prostate Cancer? *Adv in Prostate Cancer*
     2002;6:10-14.

192. Schrump DS, Nguyen DM, Kunst TE, Hancox A, **Figg WD**, Steinberg
     SM, Pishchik V, Becerra Y. Phase I Study of Sequential
     Deoxyazacytidine/Depsipeptide Infusion in Patients with
     Malignancies Involving Lungs or Pleura. *Clin Lung Cancer*
     2002;4:186-92.

193. Ando Y, Price DK, Dahut WL, Cox MC, Reed E, **Figg WD**.
     Pharmacogenetic Associations of CYP2C19 Genotype with in vivo
     Metabolisms and Pharmacological Effects of Thalidomide. *Cancer Bio
     Ther* 2002;1:669-73.

194. Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, **Figg
     WD**, Wainer I, Chaissang C, Li MZ, Hawkins WJ. A Phase I trial of
     Depsipeptide (FR901228) in patients with Advanced Cancer. *J
     Experimental Therap Oncol* 2002;2:325-32.

195. Blagosklonny MV, Darzynkiewicz Z, **Figg WD**. Flavopiridol
     Inversely Affects p21(WAF1/CIP1) and p53 and Protects p21-Sensitive
     Cells from Paclitaxel. *Cancer Biol Ther* 2002;1:420-5.

196. Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ,
     Melillo G, Zhai S, **Figg WD**, Swain SM, Senderowicz AM. Phase I
     clinical and pharmacokinetic study of flavopiridol administered as
     a daily 1-hour infusion in patients with advanced neoplasms. *J
     Clin Oncol* 2002;20:4074-82.

197. Zogakis TG, Costouros NG, Kruger EA, Forbes S, He M, Qian M,
     Feldman AL, **Figg WD**, Alexander HR, Liu ET, Kohn EC, Libutti SK.
     Microarray gene expression profiling of angiogenesis inhibitors
     using the rat aortic ring assay. *Biotechniques* 2002;33:664-70.

198. Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G,
     Ding I, Headlee D, **Figg WD**, Sausville EA, Senderowicz AM.
     Flavopiridol-related Pro-inflammatory Syndrome Associated with
     Induction of Interleukin-6. *Clin Cancer Res* 2003;9:562-570.

199. Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann
     RA, Arbuck S, Murgo A, Melillo G, Fuse E, **Figg WD**. Clinical
     Pharmacology and Pharmacogenetics of Flavopiridol 1-Hour IV
     Infusion in Patients with Refractory Neoplasms. *AntiCancer Drugs*
     2003;14:125-35.

200. Fine HA, Wen PY, Maher EA, Viscosi E, Batchelor T, Lakhani N,
     **Figg WD**, Purow BJ, Borkowf C. A Phase II Trial of Thalidomide
     and Carmustine for Patients with Recurrent High Grade Gliomas. *J
     Clin Oncol* 2003;21:2299-304.

201. Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK,
     **Figg WD**. Current status of thalidomide and its role in the
     treatment of metastatic prostate cancer. *Critical Rev Oncol
     Hematol* 2003;46:Suppl 49-57.

202. Gulley JG, **Figg WD**, Dahut WL. Treatment options for Androgen
     Independent Prostate Cancer. *Clin Adv in Hematol and Oncol*
     2003;1:49-57.

203. Lakhani NJ, Sarkar MA, Venitz J, **Figg WD**. 2-Methoxyestradiol, A
     Promising Anticancer Agent. *Pharmacotherapy* 2003;23:165-72.

204. Uchio EM, Linehan WM, **Figg WD**, Walther MM. A Phase I Study of
     Intravesical Suramin for the Treatment of Superficial Transitional
     Cell Carcinoma of the Bladder. *J Urol* 2003;169:357-60.

205. Horne MK 3rd, **Figg WD**, Arlen P, Gulley J, Parker C, Lakhani N,
     Parnes H, Dahut WL. Increased Frequency of Venous Thromboembolism
     with the Combination of Docetaxel and Thalidomide in Patients with
     Metastatic Androgen Independent Prostate Cancer. *Pharmacotherapy*
     2003;23:315-8.

206. Hamilton M, Dahut W, Brawley O, Davis P, Wells-Jones T, Kohler D,
     Duray P, Liewehr DJ, Lakhani N, Steinberg SM, **Figg WD**, Reed E.
     A Phase I/II Study of High-Dose Tamoxifen in Combination with
     Vinblastine in Patients with Androgen Independent Prostate Cancer.
     *Acta Oncol* 2003;42:195-201.

207. Leonard GD, Dahut WL, Gulley J, Arlen P, **Figg WD**. Docetaxel and
     Thalidomide as a Treatment Option in Androgen Independent
     Non-metastic Prostate Cancer. *Rev Urol* 2003;5(Suppl 3):S65-70.

208. Sparreboom A, Danesi R, Ando Y, Chan J, **Figg WD**.
     Pharmacogenomics of ABC Transporters and its Role in Cancer
     Chemotherapy. *Drug Resistance Updat* 2003;6:71-84.

209. Rudek MA, Bauer KS, Lush RM, Stinson SF, Senderowicz AM, Headlee
     DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, **Figg WD**.
     Clinical Pharmacology of Flavopiridol Following a 72-Hour
     Continuous Infusion. *Ann Pharmacother* 2003;37:1369-74.

210. Kurdziel KA, **Figg WD**, Carrasquillo JA, Huebsch S, Whatley M,
     Sellers D, Libutti SK, Pluda JM, Dahut W, Reed E, Bacharach SL.
     Using Positron Emission Tomography 2-Deoxy-2-\[18F\]
     Fluro-D-Glucose, 11CO, and 15O-water for Monitoring Androgen
     Independent Prostate Cancer. *Mol Imaging Biol* 2003;5:86-93.

211. Luzzio FA, Mayorov AV, Ng SS, Kruger EA, **Figg WD**. Thalidomide
     Metabolites and Analogs. Part 3: Synthesis and Antiangiogenic
     Activity of the Teratogenic and TNFalpha-Modulatory Thalidomide
     Analog 2-(2,6-Dioxopiperidine-3-yl)phthalimidine. *J Med Chem*
     2003;46:3793-9.

212. Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, **Figg WD**. Factors
     involved in the pharmacokinetics of COL-3, a matrix
     metalloproteinase inhibitor, in patients with refractory metastatic
     cancer: clinical and experimental studies. *J Clin Pharmacol*
     2003;43:1124-35.

213. Ng SS, Gutschow M, Weiss M, Hauschildt S, Teubert U, Hecker TK,
     Luzzio FA, Kruger EA, Eger K**, Figg WD**. Antiangiogenic Activity
     of N-Substituted and Tetrafluorinated Thalidomide Analogues.
     *Cancer Res* 2003;63:3189-94.

214. Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, McNally J,
     Conrads TP, Veenstra TD, Martinez A, Cuttitta F, Price DK, **Figg
     WD**. Anti-angiogenic activity of human endostatin is HIF-1-
     independent in vitro and sensitive to timing of treatment in a
     human saphenous vein assay. *Mol Cancer Ther* 2003;2:845-54.

215. Lakhani NJ, Venitz J, **Figg WD**, Sparreboom A. Pharmacogenetics
     of Estrogen Metabolism and Transport in Relation to Cancer. *Curr
     Drug Metab* 2003;4:505-13.

216. Ng SS, **Figg WD**. Antitumor Activity of Herbal Supplements in
     Human Prostate Cancer Xenografts Implanted in Immunodeficient Mice.
     *Anticancer Res* 2003;23:3585-90.

217. Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically
     Modified Tetracyclines as Matrix Metalloproteinase Inhibitors in
     Anti-Cancer Drug Development. In Mohan RM (Editor) [Research
     Advances in Cancer]{.underline}, Vol 3, Part II, 2003. Published by
     Global Research Network, Kerala, India.

218. Lepper ER, Swain SM, Tan AR, **Figg WD**, Sparreboom A.
     Liquid-chromatographic determination of erlotinib (OSI-774), an
     epidermal growth factor receptor tyrosine kinase inhibitor*. J
     Chromatogr B* 2003;796:181-8.

219. **Figg WD**, Cox MC. Pharmacy Education: Back to the Basics?
     *Pharmacotherapy* 2003;23:1381-90.

220. **Figg WD**, Cox MC. Pharmacy Education: Authors Response.
     *Pharmacotherapy* 2004;24:691-3.

221. Passaro MD, Piquion J, Mullen N, Sutherland D, Zhai S, **Figg WD**,
     Blye R, Nieman LK. Luteal phase dose-response relationships of the
     antiprogestin CDB-2914 in normally cycling women. *Hum Reprod*
     2003;18:1820-1827.

222. ten Tije AJ, Loos WJ, Verweij J, Baker SD, Dinh K, **Figg WD**,
     Sparreboom A. Disposition of polyoxyethylated excipients in humans:
     Implications for drug safety and formulation approaches. *Clin
     Pharmacol Ther* 2003;74:509-10.

223. Retter AS, **Figg WD**, Dahut WL. The Combination of Antiangiogenic
     and Cytotoxic Agents in the Treatment of Prostate Cancer. *Clin
     Prostate Cancer* 2003;2:153-9.

224. Hussain MM, Kotz H, Minasian L, Premkumar A, Sarosy G, Reed E, Zhai
     S, Steinberg S, Raggio M, Oliver VK, **Figg WD**, Kohn EC. A Phase
     II Trial of Carboxyamido-triazole in Patients with Relapsed
     Epithelial Ovarian Cancer. *J Clin Oncol* 2003;21:4356-63.

225. Macpherson GR, Ng SSW, Lakhani NJ, Price DK, Venitz J, **Figg WD**.
     Anti-angiogenesis Therapeutic Strategies in Prostate Cancer. In
     Cher ML, Honn KV, Raz A (Editors) [Prostate Cancer: New Horizons in
     Research and Treatment]{.underline}. Published by Kluwer Academic
     Publishing, New York, NY, 2003, 317-331.

226. Franks ME, Macpherson GR, Lepper ER, **Figg WD**, Sparreboom A. New
     Directions in Cancer Research 2003: Technological Advances in
     Biology, Drug Resistance, and Molecular Pharmacology. *Drug Resist
     Updat* 2003;6:301-12.

227. Sparreboom A, Cox MC, Acharya MR, **Figg WD**. Herbal Remedies in
     the United States Potential Adverse Interactions with Anticancer
     Agents. *J Clin Oncol* 2004;22:2489-503.

228. Price DK, Franks ME, **Figg WD**. Genetic Variations in the Vitamin
     D Receptor, Androgen Receptor and Enzymes that Regulate Androgen
     Metabolism. *J Urol* 2004;171:S45-49.

229. Ehrlich A, Booher S, Becerra Y, Borris DL, **Figg WD**, Turner ML,
     Blauvelt A. Micellar Paclitaxel Improves Severe Psoriasis in a
     Prospective Phase II Pilot Study*. J Am Acad of Derm*
     2004;50:533-40.

230. Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, **Figg
     WD**, Albert PS, Menard C, Camphausen K. Urinary VEGF and MMP
     levels as Predictive Markers of 1-year Progression-free Survivial
     in Cancer Patients Treated with Radiation Therapy: A longitudinal
     Study of Protein Kinetics throughout Tumor Progression and Therapy.
     *J Clin Oncol* 2004;22:499-506.

231. Franks ME, Macpherson GR, **Figg WD**. Thalidomide. *Lancet*
     2004;363:1802-11.

232. **Figg WD**, McLeod HL (Editors) [Handbook of Anticancer
     Pharmacokinetics and Pharmacodynamics]{.underline}. Published by
     Humana Press, Totowa, NJ, 2004.

233. Acharya MR, **Figg WD**. Book Review: Handbook of Pharmaceutical
     Biotechnology. *Annals of Pharmacotherapy* 2004;38:178.

234. Ng SS, **Figg WD**, Sparreboom A. Taxane-Mediated Antiangiogenesis
     In Vitro: Influence of Formulation Vehicles and Binding Proteins.
     *Cancer Res* 2004;64:821-4.

235. Tohnya TM, Ng SS, Dahut WL, Wright JJ, Arlen PM, Gulley JL, Parker
     C, Zeldis J, **Figg WD**. A Phase I Study of Oral CC-5013
     (lenalidomide, Revlimid), a Thalidomide Derivative, in Patients
     with Refractory Metastatic Cancer. *Clin Prostate Cancer*
     2004;2:241-3.

236. Cox MC, **Figg WD**, Thurman PW. No Rational Theory for Drug
     Pricing. *J Clin Oncol* 2004;22;962-3.

237. Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW**, Figg WD**,
     Sparreboom A. Determination of MS-275, a Novel Histone Deacetylase
     Inhibitor, in Human Plasma by Liquid Chromatography-Electrospray
     Mass Spectrometry. *J Chromatogr B* 2004;804:289-94.

238. McDonald DM, Teicher BA, Stetler-Stevenson W, Ng SS, **Figg WD**,
     Folkman J, Hanahan D, Auerbach R, O'Reilly M, Herbst R, Cheresh D,
     Gordon M, Eggermont A, Libutti SK. Report from the Society for
     Biological Therapy and Vascular Biology Faculty of the NCI Workshop
     on Angiogenesis Monitoring. *J Immunonotherap* 2004;27:161-175.

239. Luzzio FA, **Figg WD**. Thalidomide Analogues: Derivatives of an
     Orphan Drug with Diverse Biological Activity. *Expert Opinion on
     Therapeutic Patents* 2004;14:215-29.

240. **Figg WD**, Franks ME, Venzon D, Duray P, Cox MC, Linehan WM,
     Van-Bingham W, Eastham JA, Reed E, Sartor O. Gleason Score and
     Pretreatment PSA in Survival Amoung Patients with Stage D2 Prostate
     Cancer. *World J Urol* 2004;22:425-30.

241. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Parr AL, **Figg
     WD**, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo
     JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. Evaluation of
     Biologic End Points and Pharmacokinetics in Patients with
     Metastatic Breast Cancer after Treatment with Erlotinib, an
     Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. *J Clin
     Oncol*, 2004;22:3080-90.

242. Lepper ER, Ng SS, Gutschow M, Weiss M, Hauschildt S, Hecker TK,
     Luzzio FA, Eger K, **Figg WD**. Comparative Molecular Field
     Analysis and Comparative Molecular Similarity Indices Analysis of
     Thalidomide Analogues as Angiogenesis Inhibitors. *J Med Chem*
     2004;47:2219-27.

243. Tohnya TM, Kim S, Fine HA, Dunn L, **Figg WD**, Sparreboom A.
     Determination of SU5416, a Novel Angiogenesis Inhibitor, in Human
     Plasma by Liquid Chromatography. *J Chromatogr B* 2004;805;135-40.

244. Singh A, **Figg WD**. Upregulation of the Androgen Receptor During
     Prostate Cancer Progression. *Cancer Biol Therapy* 2004;3:284-5.

245. Lepper ER, Hicks JK, Verweij J, Zhai S, **Figg WD,** Sparreboom A.
     Determination of Midazolam in Human Plasma by liquid chromatography
     with mass-spectrometric detection. *J Chromatogr B*
     2004;806:305-10.

246. Lakhani NJ, Sparreboom A, Dahut WL, Venitz J, **Figg WD**.
     Determination of the Antiangiogenesis Agent 2-Methoxyestradiol
     (2ME2) in Human Plasma by Liquid Chromatography with Ultraviolet
     Detection. *J Chromatogr B* 2004;806:289-93.

247. Ng SS, Macpherson GR, Gutschow M, Eger K, **Figg WD**. Antitumor
     Effects of Thalidomide Analogs in Human Prostate Cancer Xenografts
     Implanted in Immunodeficient Mice. *Clin Cancer Res*
     2004;10:4192-7.

248. Acharya MR, Baker SD, Verweij J, **Figg WD**, Sparreboom A.
     Determination of fraction unbound docetaxel using microequilibrium
     dialysis. *Anal Biochem* 2004;331:192-4.

249. Acharya MR, Venitz J, **Figg WD**. What Dose do you Start with and
     How Quickly do you Increase that Dose? *Am Pharmaceutic
     Outsourcing* 2004;5:1-4.

250. Cox MC, Smith NF, **Figg WD**. The Use of Thalidomide in Renal
     Cancer. *American Society of Clinical Oncology 2004 Educational
     Book* 2004;249-51

251. Price DK, **Figg WD**. H-Tert-Immortalized Endothelial Cells: An
     Important New Research Tool. *Cell Cycle* 2004;3:789.

252. Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM,
     Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM,
     **Figg WD**. A Randomized Phase II Trial of Docetaxel plus
     Thalidomide in Androgen-Independent Prostate Cancer*. J Clin Oncol*
     2004;22:2532-9.

253. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC,
     Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B,
     Stein WD, Choyke P, Balis F, **Figg WD**, Fojo T. A Phase I/II
     Study of Infusional Vinblastine with the P-Glycoprotein Antagonist
     Valspodar (PSC-833) in Renal Cell Carcinoma. *Clin Cancer Res*
     2004;10:4724-33.

254. Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C,
     Brahim JS, Steinberg SM, **Figg WD**, Swain SM. Phase I Trial of
     the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination
     with Docetaxel in Patients with Metastatic Breast Cancer. *Clin
     Cancer Res* 2004;10:5038-47.

255. Cox M, Liu Y, **Figg WD**. Antiangiogenesis in Prostate Cancer.
     *Cancer Therapy* 2004;2:121-9.

256. Acharya MR, Venitz J, **Figg WD**, Sparreboom A. Chemically
     modified Tetracyclines as Inhibitors of Matrix Metalloproteinases.
     *Drug Resist Updat* 2004;7:195-208.

257. Paoluzzi L, **Figg WD**. Histone Deacetylase Inhibitors are Potent
     Radiation Protectants. *Cancer Biol Ther* 2004;3:612-3.

258. Macpherson G, **Figg WD**. Small molecule-mediated anti-cancer
     therapy via hypoxia inducible factor-1 blockade. *Cancer Biol The*
     2004;3:503-4.

259. Paoluzzi L, Singh AS, Price DK, Danesi R, Mathijssen RH, Verweij J,
     **Figg WD**, Sparreboom A. Influence of genetic variants in
     *UGT1A1* and *UGT1A9* on the *in vivo* glucuronidation of SN-38. *J
     Clin Pharmacol* 2004;44:854-60.

260. Hwang K, Piekarz RL, Bates SE, **Figg WD**, Sparreboom A.
     Determination of the cyclic depsipeptide FK228, a histone
     deacetylase inhibitor, by liquid chromatography-mass spectrometry.
     *J Chromatogr B* 2004;809:81-86.

261. Price DK, **Figg WD**. Mutations in the EGFR: The Importance of
     Genotyping. *Cancer Bio Ther* 2004;3:434-5.

262. Mathijssen RHJ, De Jong FA, Van Schaik RHN, Lepper ER, Friberg L,
     Rietveld T, De Bruijn P, Graveland WJ, **Figg WD**, Verweij J,
     Sparreboom A. Prediction of Irinotecan Pharmacokinetics by use of
     Cytochrome P4503A4 Phenotyping Probes. *J Natl Canc Inst,*
     2004;96:1585-92.

263. Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA,
     Kuwabara T, Venzon D, Margo A, Headlee D, Sausville EA, Effects of
     Alpha1-Acid Glycoprotein on the Clinical Pharmacokinetics of
     7-hydroxystaurosporine. **Figg WD**. *Clin Cancer Res*
     2004;10:6840-6.

264. Ng SSW, **Figg WD**. Upregulation of Endogenous Angiogenesis
     Inhibitors: A Mechanism of Action of Metronomic Chemotherapy.
     *Cancer Biol Therapy* 2004;3:1212-3.

265. Acharya MR, **Figg WD**. Histone deacetylase inhibitor enhances the
     anti-leukemic activity of an established nucleoside analogue.
     *Cancer Bio Therapy* 2004;3:719-20.

266. Tohnya TM, Hwang K, Lepper ER, Fine HA, Dahut WL, Venitz J,
     Sparreboom A, **Figg WD**. Determination of CC-5013, a Thalidomide
     Analogue, in Human plasma by liquid Chromatography-mass
     Spectrometry. *J Chromatogr B* 2004;811:135-41.

267. Smith NF, **Figg WD**, Sparreboom A. Recent Advances in
     Pharmacogenetic Approaches to Anti-Cancer Drug Development. *Drug
     Develop Res* 2004;51:1-21.

268. Retter AS, **Figg WD**, Dahut WL. A Case Study of Docetaxel and
     Thalidomide in Androgen Independent Prostate Cancer. *Am J of Oncol
     Rev* 2004;3:618-21.

269. Cox MC, Lepper ER, **Figg WD**, Sparreboom A. Use of St. John's
     Wort by Cancer Patients: Novel Insights and Safety Considerations.
     *J Cancer Integrative Med* 2004;2:125-136.

270. Macpherson GR, Singh A, Bennett C, Venzon D, Liewehr D, Franks M,
     Dahut B, Price DK, **Figg WD**. Genotypic and functional analysis
     of the D104N variant of Human Endostatin. *Cancer Bio Therap*
     2004;3:1298-303.

271. Tohnya TM, **Figg WD**. Immunomodulation of Multiple Myeloma.
     *Cancer Bio Therapy* 2004;3:1060-1.

272. Baker SD, Li J, ten Tije AJ, **Figg WD**, Graveland W, Verweij J,
     Sparreboom A. Relationship of systemic Exposure to Unbound
     Docetaxel and Neutropenia. *Clin Pharmacol Ther* 2005;77:43-53.

273. **Figg WD**, Liu Y, Arlen P, Gulley J, Steinberg SM, Liewehr DJ,
     Cox MC, Zhai S, Cremers S, Parr A, Yang X, Chen CC, Jones E, Dahut
     WL. A Randomized Phase II Trial of Ketoconazole Plus Alendronate
     versus Ketoconazole Alone in Patients with Androgen-Independent
     Prostate Cancer and Bone Metastases. *J Urol* 2005:173:790-6.

274. Gulley JL, **Figg WD**, Steinberg SM, Carter J, Hussain M, Dahut
     WL. A Prospective Analysis of the Time to Normalization of Serum
     Androgens Following 6 Months of Androgen Deprivation Therapy in
     Patients on a Randomized Phase III Clinical Trial Using Limited
     Hormonal Therapy. *J Urol* 2005;173:1567-71.

275. Longoria RL, Cox MC, **Figg WD**. Antiangiogenesis: Possible
     Treatment Option for Prostate Cancer? Clinical Prostate Cancer.
     *Clin Prostate Cancer* 2005;4:197-202.

276. Cox MC, Permenter M, **Figg WD**. Angiogenesis in Prostate Cancer:
     Important Laboratory and Clinical Findings. *Cur Oncol Rep*
     2005;7:215-9.

277. Singh A, **Figg WD**. In Vivo Models of Prostate Cancer Metastasis
     to Bone. *J Urol* 2005;174:820-6.

278. Singh AS, Price DK, **Figg WD**. Polymorphisms in the Androgen
     Receptor and Genes that Metabolize Androgens in the Development of
     Prostate Cancer. *Nature Clin Pract Urol* 2005;2:101-107.

279. Palmieri D, Halverson D, Ouatas T, Horak C, Salerno M, Johnson J,
     **Figg WD**, Hollingshead M, Hursting S, Berrigan D, Steinberg SM,
     Merino MJ, Steeg PS. Medroxyprogesterone acetate Elevation of Nm
     23-H1 Metastasis Suppressor Expression in Hormone Receptor-Negative
     Breast Cancer. *J Natl Cancer Inst* 2005;97:632-42.

280. Scripture CD, **Figg WD**, Sparreboom A. Paclitaxel Chemotherapy:
     From Empiricism Toward a Mechanism based Formulation Strategy.
     *Ther Clin Risk Management* 2005;1:107-14.

281. Fuse E, Kuwabara T, Sparreboom A, Sausville EA, **Figg WD**. A
     Review of UCN-01 Development: A Lesson in the Importance of
     Clinical Pharmacology. *J Clin Pharmacology* 2005;45:394-403.

282. Lepper ER, Nooter K, Verweij J, Acharya M, **Figg WD**,
     Sparreboom A. Mechanisms of Resistance to Anticancer Drugs: the
     role of the Polymorphic ABC Transporters ABCB1 and ABCG2.
     *Pharmacogenomics* 2005;6:115-38.

283. Cox MC, **Figg WD**. Book Review: Management of Prostate Cancer.
     *Annals of Pharmacotherapy* 2005;39: 390-1.

284. Sparreboom A, Scripture CD, Trieu V, William PJ, De T, Yang A,
     Beals B, **Figg WD**, Hawkins MJ, Desai N, Comparative Preclinical
     and Clinical Pharmacokinetics of a Cremophor-Free,
     Protein-Stabilized, Nanoparticle Formulation of Paclitaxel
     (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). *Clin
     Cancer Res* 2005;11:4136-43.

285. Ryan Q, Headlee D, Acharya MR, Sparreboom A, Trepel J, Ye J, **Figg
     WD**, Hwang K, Chung E, Murgo A, Melillo G, Elsayed Y, Mongo M,
     Kalnitskiy M, Zwiebel J, Sausville EA. A Phase I and
     Pharmacokinetic Study of MS-275, a Histone Deacetylase in Patients
     with Advanced Solid Tumor or Lymphoma. *J Clin Oncol*
     2005;23:3912-22.

286. Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N,
     Hamasaki M, Yasui H, Munshi N, **Figg WD**, Anderson KC.
     Anti-myeloma Activity of Two Novel N-substituted and
     Tetraflourinated Thalidomide Analogues. *Leukemia* 2005;19:1253-61.

287. Scripture CD, Szebeni J, Loos WJ, **Figg WD**, Sparreboom A.
     Comparative in vitro properties and Clinical Pharmacokinetics of
     Paclitaxel following the Administration of Taxol and Paxene.
     *Cancer Biol Therap* 2005;4:555-560.

288. Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, **Figg
     WD**. Determination of 2-methoxy-estradiol in Human Plasma, using
     Liquid Chromatography/Tandem-mass spectrometric Detection. *Rapid
     Commun Mass Spectrom* 2005;19:1176-82.

289. **Figg WD**, Retter A, Steinberg SM, Dahut WL. Inhibition of
     Angiogenesis: Thalidomide or Low Molecular Weight Heparin? *J Clin
     Oncol* (letter) 2005;23:2113-4.

290. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, **Figg
     WD**, Zhai S, Beresneva T, Steinberg SM, Seidel GD, Alexander HR. A
     Phase I Study of Hepatic Arterial Melphalan Infusion and Hepatic
     Venous Hemofiltration Using Percutaneously Placed Catheters in
     Patients with Unresectable Hepatic Malignancies. *J Clin Oncol*
     2005;23:3465-74.

291. D'Amico AV, Chen MH, Cox MC, Dahut W, **Figg WD**.
     Prostate-Specific Antigen Response Duration Risk of Death for
     Patients with Hormone-Refractory Metastatic Prostate Cancer. *Urol*
     2005;66:571-6.

292. Chau CH, **Figg WD**. Molecular and Phenotypic Hetergeneity of
     Hormone-Refractory Metastatic Prostate Cancer. *Cancer Biol Ther*
     2005;4:166-7.

293. Sparreboom A, Loos WJ, Burger H, Sissung TM, Verweij J, **Figg
     WD**, Nooter K, Gelderblom H. Effect of ABCG2 421C\>A Genotype on
     the Oral Bioavailability of Topotecan. *Cancer Bio Ther*
     2005;4:650-8.

294. Lepper E, Baker SD, Parmenter M, Ries N, van Schaik RHN, Schenk PW,
     Price DK, Ahn D, Smith NF, Cusatis G, Ingersoll RG, Bates SE,
     Mathijssen RHJ, Verweij J, **Figg WD**, Sparreboom A. Effect of
     Common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the
     Cytochrome P4503A Phenotyping Probe Midazolam in Cancer Patients.
     *Clin Cancer Res* 2005;11:7398-7404.

295. Smith NF, Acharya MR, Desai N, **Figg WD**, Sparreboom A.
     Identification of OATP1B3 as a high-affinity hepatocellular
     transporter of paclitaxel. *Cancer Biol Ther* 2005;4:815-8.

296. Acharya MR, Sparreboom A, Ventiz J, **Figg WD**. Rational
     Development of Histone Deacetylase Inhibitors as Anticancer Agents:
     A Review. *Mol Pharmacol* 2005;68:917-32.

297. Sparreboom A, **Figg WD**. Recent Advances in Pharmacogenetic
     Approaches to Cancer Chemotherapy. *Inv New Drugs* 2005;23:511.

298. Best CJM, Gillespie JW, Perlmutter MA, Gathright Y, Gadisetti C,
     Duray PH, Gonzalez S, Velasco A, Linehan WM, Price D, **Figg WD**,
     Emmert-Buck MR, Chuaqui RF. Molecular Alterations in Primary
     Prostate Cancer Androgen Ablation Therapy. *Clin Cancer Res*
     2005;11:6823-6834.

299. Smith NF, **Figg WD**, Sparreboom A. Role of the liver-specific
     transporters OATP1B1 and OATP1B3 in governing Drug Elimination.
     *Exp Opinion Drug Metabol Toxicol* 2005;1:429-45.

300. Posadas EM, Gulley J, Arlen PM, Trout A, Parnes HL, Wright J,
     Steinberg SM, Lee MJ, Chung EJ, Trepel JB, Sparreboom A, Chen C,
     Jones E, **Figg WD**, Dahut WL. A Phase II Study of Oral Perifosine
     in Androgen Independent Prostate Cancer. *Cancer Biol Ther*
     2005;4:1133-7.

301. Rozhansky F, Chen MH, Cox MC, Dahut W, **Figg WD**, D'Amico AV. PSA
     Velocity and Survival for Patients with Hormone Refractory
     Metastatic Prostate Carcinoma. *Cancer* 2005;106:63-67.

302. Scripture CD, **Figg WD**, Sparreboom A. The Role of Drug
     Metabolizing Enzymes in Clinical Responses to Chemotherapy. *Expert
     Opin Drug Metab Toxicol* 2005;2:17-25.

303. Chau CH, Permenter MG, Steinberg SM, Dahut WL, Price DK, **Figg
     WD**. Polymorphism of the Hypoxia Inducible Factor 1Alpha Gene may
     Confer Susceptibility to Androgen-Independent Prostate Cancer.
     *Cancer Biol Ther* 2005;4:1222-5.

304. Scripture CD, Sparreboom A, **Figg WD**. Modulation of Cytochrome
     P450 Activity: Implications for Cancer Therapy. *Lancet Oncol*
     2005;6:780-9.

305. Cox MC, Scripture CD, **Figg WD**. Leuprolide acetate given by a
     Subcutaneous Extended Release Injection: Less of a Pain? *Expert
     Rev Anticancer Ther*, 2005;5:605-11.

306. Tkacz V, Tohnya T, **Figg WD**. Cyclooxygenase-2 and Angiogenesis
     in Prostate Cancer. *Cancer Biol Ther* 2005;4:813-4.

307. Sharifi N, Dahut W, Steinberg SM, **Figg WD**, Tarassoff C, Arlen
     P, Gulley JL. A Retrospective Study of the Time to Clinical End
     Points for Advanced Prostate Cancer. *Br J Urol* 2005;96:985-9.

308. Luzzio FA, Duveau DY, Lepper E, **Figg WD**. Synthesis of Racemic
     5-Hydroxy-3-Phthalimidoglutarimide. A Metabolite of Thalidomide
     Isolated from Human Plasma. *J Org Chem* 2005;70:10117-20.

309. **Figg WD**. Development of Thalidomide as an Angiogenesis
     Inhibitor for the Treatment of Androgen-Independent Prostate
     Cancer. *Clin Pharmacol Therap* 2006;79:1-8.

310. Acharya MR, Sparreboom A, Sausville EA, Conley B, Doroshow JH,
     Venitz J, **Figg WD**. Interspecies differences in protein binding
     of MS-275, a Novel Histone Deacetylas Inhibitor. *Cancer Chemother
     Pharmacol* 2006:57:275-81.

311. Chau CH, **Figg WD**. Whole or Partial Vessel Outgrowth Assays. In
     Staton CA, Lewis C, Bicknell R (Editors) [Angiogenesis Assays: A
     Critical Appraisal of Current Techniques]{.underline}. Published by
     Wiley and Sons, New York, NY, 2006:105-121.

312. Smith N, Sparreboom A, **Figg WD**. Pharmacogenetics of Irinotecan
     Metabolism and Transport: An Update. *Toxicol In vitro*
     2006;20:163-75.

313. Hwang K, Scripture CD, Gutierrez M, Kummar S, **Figg WD**,
     Sparreboom A. Determination of the Heat Shock Protein 90 Inhibitor
     17-dimethylamino-ethylamino-17-demethoxygelanamycin (17-DMAG) in
     Plasma by Liquid Chromatography Electrospray Mass Spectrometry. *J
     Chromatogr* *B* 2006;830:35-40.

314. Acharya MR, Karp JE, Sausville EA, Hwang K, Ryan Q, Gojo I, Venitz
     J, **Figg WD**, Sparreboom A. Factors affecting the
     pharmacokinetics profile of MS-275, a Novel Histone Deacetylase
     Inhibitor, in Patients with Cancer. *Inv New Drugs*,
     2006;24:367-75.

315. Singh AS, Macpherson GR, Ng S, Price DK, Schimmel D, **Figg WD**.
     Evaluation of Human Fetal Bone Implants in SCID mice as a Model of
     Prostate Cancer Bone Metastasis. *Oncol Report* 2006;15:519-24.

316. Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally
     D, Parr A, Nguyen D, Yang X, Steinberg SM, Venitz Jurgen,
     Sparreboom A, **Figg WD**. Phase I Clinical Trial of Oral
     2-methoxyestradiol (2ME2), an Antiangiogenesis and Apoptotic Agent,
     in Patients with Solid Tumors. *Cancer Biol Therap* 2006;5:22-7.

317. Travis LB, Rabkin CS, Brown LM, Allan JM, Alter BP, Ambrosone CB,
     Begg CB, Caporaso N, Chanock S, DeMichele A, **Figg WD**,
     Gospodarowicz MK, Greene MH, Hall EJ, Hisada M, Inskip P,
     Kleinerman R, Little JB, Malkin D, Ng AK, Offit K, Pui CH, Robinson
     LL, Rothman N, Shields PG, Strong L, Taniguchi T, Tucker MA, Wittes
     RE. Cancer Survivorship -- Genetic Susceptibility and Second
     Primary Cancers: Research Strategies and Recommendations. *J Natl
     Cancer Inst* 2006;98:15-25.

318. Scripture CD, **Figg WD**, Sparreboom A. Peripheral Neuropathy
     Induced by Taxane Chemotherapeutics: Recent Insights. *Cur
     Neuropharmacol* 2006;4:165-72.

319. Cox MC, Dahut WL, **Figg WD**. The use of Thalidomide in
     Androgen-Independent Prostate Cancer. *J Urol Oncol* 2006;24:246-9.

320. Parnes H, **Figg WD**. Prostate Cancer Chemoprevention.
     *Pharmacotherapy* (letter) 2006;26:1533.

321. Lepper ER, Burger H, van Schaik RH, van Oosterom AT, de Bruijn EA,
     Guetens G, Prenen H, de Jong FA, Baker SD, Bates SE, **Figg WD**,
     Verweij J, Sparreboom A, Nooter K. Association of Enzymes and
     Transporter Genotypes with the Pharmacokinetics of Imatinib. *Clin
     Pharmacol Therap* 2006;80:192-201.

322. Sissung TM, Price DK, Sparreboom A, **Figg WD**. The
     Pharmacogenetics and Regulation of CYP1B1 -- Implications in
     Hormone Mediated Tumor Metabolism and a Novel Target for
     Therapeutic Intervention. *Mol Cancer Res* 2006;4:135-50.

323. **Figg WD**, Dunn L, Liewehr D, Thurman P, Steinberg S, Barrett JC,
     Birkinshaw J. Scientific Collaboration Results in Higher Citation
     Rates of Published Articles. *Pharmacotherapy* 2006;26:759-67.

324. De Marzo AM, Platz EA, Epstein JI, Ali T, Ballis A, Chan TY, Cheng
     L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Fine S, Iczkowski
     KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi
     C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga
     H, Sebo T, Sesterhenn IA, Shah R, Signoretti S, Simko J, Thomas G,
     Troncoso P, Tsuzuki T, van Leenders GJLH, Yang X, Zhou M, **Figg
     WD**, Hoque A, Lucia MS. A Working Group Classification of Focal
     Prostate Atrophy Lesions. *Am J Surg Path* 2006;30:1281-91.

325. Erratum: A Working Group Classification of Focal Prostate Atrophy
     Lesions. *Am J Surg Path* 2006;30:1489.

326. Lepper ER, Smith NF, Cox MC, Scripture CD, **Figg WD**. Thalidomide
     Metabolism and Hydrolysis: Mechanisms and Implications. *Current
     Drug Metabolism* 2006;7:677-85.

327. Scripture CD, **Figg WD**. Drug Interactions in Cancer Treatment.
     *Nature Rev Cancer* 2006;6:546-58.

328. Scripture C, **Figg WD**. Erratum. Drug Interactions in Cancer
     Therapy. *Nature Rev Cancer* 2006;6:741.

329. **Figg WD**, Cox MC, Alchalabi T, Dahut WL. Angiogenesis Inhibitors
     in Prostate Cancer. In Dawson N, Kelly WK (Editors) [Prostate
     Cancer: Translational and Emerging Therapies.]{.underline}
     Published by Willey-Liess Publications, New York, NY, 2006,
     pp127-143.

330. Warfel NA, Lepper E, Zhang C, **Figg WD**, Dennis P. Importance of
     the Stress Kinase p38 in Mediating the Direct Cytotoxic Effects of
     the Thalidomide Analogue, CPS49, in Cancer Cells and Endothelial
     Cells. *Clin Cancer Res* 2006;12:3502-9.

331. Sparreboom A, **Figg WD**. Identifying Sources of Interindividual
     Pharmacokinetic Variability with Population Modeling. *Clin Cancer
     Res* 2006;12:1951-3.

332. Ahlers CM, **Figg WD**. ETS-TMPRSS2 Fusion Gene Products in
     Prostate Cancer. *Cancer Biol Ther* 2006;5:254-5.

333. Ng SSW, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong
     P, **Figg WD**, Kerbal RS. Influence of Formulation Vehicle on
     Metronomic Taxane Chemotherapy Albumin-bound versus Cremophor
     EL-based Paclitaxel. *Clin Cancer Res* 2006;12:4331-8.

334. Lakhani N, Sparreboom A, Venitz J, Dahut WL, **Figg WD**. Plasma
     Protein Binding of 2-methoxyestradiol. *Anticancer Drugs*
     2006;17:977-83.

335. Gardner ER, Sparreboom A, Chu Z, **Figg WD**. Determination of
     Paclitaxel in Human Plasma by LC/MS/MS following the administration
     of Genaxol or Genetaxyl by Liquid Chromatography Tandem Mass
     Spectrometry. *Rapid Commun Mass Spectrom* 2006;20:2170-4.

336. Gulley J, Dahut W, **Figg WD**. Even More Cost Savings:
     Individualized Strategy for Dosing Leutinizing Hormone Releasing
     Hormone Agonists for Androgen-Independent Prostate Cancer. *J Oncol
     Practice* (letter) 2006;2:202.

337. Sion A, **Figg WD**. Lysyl Oxidase and Hypoxia -- Induced
     Metastases. *Cancer Biol Ther* 2006;5:909-11.

338. Ge Y, Montano I, Freebern WJ, Haggerty CM, Ponciano-Jackson D,
     Chandramouli GVR, Lepper E, **Figg WD**, Jackson SH, Gardner K.
     Selective leukemic cell killing by a Novel Functional Class of
     Thalidomide Analogs. *Blood* 2006;108:4126-35.

339. Cox MC, Low JA, Lee JJ, Walshe JM, Denduluri N, Berman A, Permenter
     MG, Petros WP, Price DK, **Figg WD**, Sparreboom A, Swain SM.
     Influence of Garlic (*allium sativum*) on the Pharmacokinetics of
     Docetaxel. *Clin Cancer Res* 2006;12:4636-40.

340. Sissung TM, Mross K, Steinberg SM, **Figg WD**, Sparreboom A,
     Mielke S. Association of ABCB1 Genotypes with Paclitaxel-Mediated
     Peripheral Neuropathy and Neutropenia. *Eur J Cancer*
     2006;42:2893-6.

341. Gardner ER, **Figg WD**, Sparreboom A. Pharmacogenomics of the
     Human ATP-Binding Cassette Transporter ABCG2. *Current
     Pharmacogenomics* 2006;4:331-44.

342. Tohnya TM, Ventiz J, Sparreboom A, **Figg WD**. Lenalidomide:
     Cancer Therapy via Antiangiogenesis and Immunomodulation. *Cur
     Cancer Therap Rev* 2006;2:223-9.

343. **Figg WD**, Chau CH. Heterogeneity in Drug Disposition Determines
     Interindividual Variability of Docetaxel Pharmacokinetics. *Cancer
     Biol Ther* 2006;5:840-1.

344. Sartor O, Alchalabi T, **Figg WD**. Assessing Progress Against
     Prostate Cancer. *Clin Genitourin Cancer* 2006;5:102-3.

345. Beverage JN, **Figg WD**. The Quantification of PSA mRNA Copies in
     Pathologically Normal Pelvic Lymph Nodes is a Viable Prognostic
     Indicator. *Cancer Biol Ther*, 2006;5:1094-5.

346. **Figg WD**, Ocker S. Prostate Cancer -- 6^th^ International
     Congress Review. *IDrug* 2006;9:675-8.

347. Smith E, Price DK, **Figg WD**. Piecing together the HIF-1 puzzle:
     the role of the CTGF as a molecular mechanism of HIF-1 regulation.
     *Cancer Biol Ther* 2006;5:1443-4.

348. Ahlers CM, **Figg WD**. Sifing Through the Multitude of Novel
     Therapies for Prostate Cancer. *Oncology* 2006:20:1792-6.

349. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox
     A, Hong JA, Chen GA, Pishchik V, **Figg WD**, Murgo AJ, Steinberg
     SM. Phase I Study of Decitabine-Mediated Gene Expression in
     Patients with Cancers Involving the Lungs, Esophagus, or Pleura.
     *Clin Cancer Res* 2006;12:5777-5785.

350. Luzzio FA, Duveau DY, **Figg WD**. A Chiral Pool Approach Toward
     the Synthesis of Thalidomide Metabolites. *Heterocycles*
     2006;70:321-334.

351. Ocker S, Price DK, **Figg WD**. DNA Microarrays: Tissue Removal and
     Processing Affects Gene Expression. *Cancer Biol Ther*
     2006;5:1608-9.

352. Smith NF, Marsh S, Scott-Horton TJ, Hamada A, Mielke S, Mross K,
     **Figg WD**, Verweij J, McLeod HL, Sparreboom A. Variants in the
     SLCO1B3 Gene: Interethnic Distribution and Association with
     Paclitaxel Pharmacokinetics. *Clin Pharmacol Therap* 2007;81:76-82.

353. Wu SL, Jones E, Gulley JL, Arlen PM, Chen CC, **Figg WD**, Dahut
     WL. Routine Interval Computed Tomography to Detect New Soft Tissue
     Disease Might Be Unnecessary in Patients with Androgen-Independent
     Prostate Cancer and Only to Bone Metastasis. *Br J Urol*
     2007;99:525-8.

354. Deeken JF, **Figg WD**, Bates SE, Sparreboom A. Toward
     Individualized Treatment Prediction of Anticancer Drug Disposition
     and Toxicity with Pharmacogenetics. *Anticancer Drugs*
     2007;18:111-26.

355. **Figg WD**, Folkman J (Editors). [Angiogenesis: An Integrative
     Approach from Science to Medicine]{.underline}. Published by
     Springer Publishing, New York, NY, 2008;1-601.

356. Lakhani NJ, Sparreboom A, Xu X, Veenstra TD, Venitz J, Dahut WL,
     **Figg WD**. Characterization of in vitro and in vivo metabolic
     pathways of the Investigational Anticancer Agent,
     2-methoxyestradiol. *J Pharmac Sci* 2007;96:1821-31.

357. Li H, Price DK, **Figg WD**. ADH1, an N-Cadherin Inhibitor,
     Evaluated in Preclinical Models of Angiogenesis and Androgen
     Independent Prostate Cancer. *Anticancer Drugs* 2007;18:563-8.

358. Gojo I, Jiemjit A, Trepel JB, Sparreboom A, **Figg WD**, Rollins S,
     Tidwell ML, Greer J, Chung EJ, Lee MJ, Gore SD, Sausville EA,
     Zwiebel J, Karp JE. Phase I and Pharmacological Study of MS275, A
     Histone Deacetylase Inhibitor, in Adults with Refractory and
     Relapsed Acute Leukemias. *Blood* 2007;109:2781-90.

359. DiLorenzo G, Autorino R, **Figg WD**, DePlacido S. Hormone
     Refractory Prostate Cancer: Where Are We Going? *Drugs*
     2007;67:1109-24.

360. **Figg WD**, Li H, Sissung T, Retter A, Wu S, Gulley JL, Arlen P,
     Wright JJ, Parnes H, Fedenko K, Latham L, Steinberg SM, Jones E,
     Chen C, Dahut WL. Preclinical and Clinical Evaluation of
     Estramustine, Docetaxel and Thalidomide Combination in Androgen
     Independent Prostate Cancer. *Br J Urol* 2007;99:1047-55.

361. Beverage JN, Sissung TM, Sion AM, Danesi R, **Figg WD**. CYP2D6
     Polymorphisms and the Impact on Tamoxifen Therapy. *J Pharm Sci*
     2007;96:2224-31.

362. Chau C, **Figg WD**. Angiogenesis Therapy. In DeVita VT, Rosenberg
     SA (Editors) [Cancer: Principles and Practice of Oncology 8^th^
     Edition]{.underline}. Published by Lippincott Williams and Wilkins,
     Philadelphia, PA 2008;527-36.

363. **Figg WD**, Chau C (Editors). [Getting into Pharmacy
     School]{.underline}. Published by Kaplan Publishing, New York, NY,
     2007.

364. Sissung TM, Gardner E, Gao R, **Figg WD**. Pharmacogenetics of
     Membrane Transporters: A Review of Current Approaches. *Methods Mol
     Biol* 2008;448:41-62.

365. Smith NF, Mani S, Schuetz EG, Yasuda K, Xi Z, Bates SE, **Figg
     WD**, Sparreboom A. Induction of Cytochrome P4503A4 by Vinblastine:
     Role of the Nuclear Receptor NR112. *Clinical Pharmacology
     Therapeut.* In press.

366. Chau CH, Dahut WL, **Figg WD**. Development of Thalidomide and Its
     IMiD Derivatives (Chapter 34). In **Figg WD**, Folkman J (Editors).
     [Angiogenesis: An Integrative Approach from Science to
     Medicine]{.underline}. Published by Spinger, New York, NY,
     2008;387-394.

367. Chau CH, **Figg WD**. Recent Advances in Angiogenesis Drug
     Development (Chapter 37). In **Figg WD**, Folkman J (Editors).
     [Angiogenesis: An Integrative Approach from Science to
     Medicine]{.underline}. Published by Spinger, New York, NY, 2008;
     421-430.

368. Di Lorenzo G, Autorino R, Perdona S, Trusso F, De Laurentiis M,
     D'Armiento M, Gallo L, Mirone V, Altieri V, **Figg WD**, De
     Placido S. Docetaxel, Vinorelbine and Zoledronic Acid as First Line
     Treatment in Patients with Hormone Refractory Prostate Cancer: A
     Phase II Study. *Eur Urol* 2007;52:1020-7.

369. **Figg WD**. The Pharm.D. Investigator in Clinical Pharmacology:
     Supply and Demand. *Clinical Pharmacology Therapeut*, In press.

370. Alchalabi T, **Figg WD**. The Additive Effect of Thalidomide to
     Chemotherapy in Androgen Independent Prostate Cancer. *Cancer Biol
     Ther* 2007;6:318-9.

371. Aragon-Ching JB, Li H, Gardner ER, **Figg WD**. Thalidomide
     Analogues as Anticancer Drugs. *Recent Patents on Anti-Cancer Drug
     Discovery,* 2007;2:167-74.

372. Lal S, Wong ZW, Jada SR, Xiang X, Chen Shu X, Ang PC, **Figg WD**,
     Lee EJ, Chowbay B. Novel SLC22A16 polymorphisms and influence on
     doxorubicin pharmacokinetics in Asian Breast Cancer Patients.
     *Pharmacogenomics* 2007;8:567-575.

373. Gills JJ, LoPiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab
     MS, Borojerdi J, Warfel NA, Gardner ER. Danish M, Hollander MC,
     Kawabata S, Tsokos M, **Figg WD**. Steeg PS, Dennis PA. Nelfinavir,
     a lead HIV protease inhibitor, is a Broad Spectrum, Anticancer
     agent that induces Endoplasmic Reticulum Stress, Autophagy and
     Apoptosis in vitro and in vivo. *Clinical Cancer Res*
     2007;13:5183-94.

374. Hamada A, Danesi R, Price DK, Sissung T, Chau C, Venzon D,
     Sparreboom A, Dahut WL, **Figg WD**. Association of a CYP17
     polymorphism with Overall Survival in Caucasian Patients with
     Androgen Independent Prostate Cancer. *Urology* 2007;70:217-20.

375. Kummar S, Gutierrez M, Gardner ER, Hwang K, Chung EJ, Lee MJ,
     Maynard K, Kalnitskiy M, Donovan E, Chen A, Melillo G, Ryan QC,
     Conley B, Sausville E, Sparreboom A, **Figg WD**, Trepel JB,
     Zwiebel J, Doroshow JH, Murgo AJ. Phase I Trial of MS-275, a
     Histone Deacetylase Inhibitor Administered Weekly, in Refractory
     Solid Tumors and Lymphoid Malignancies. *Clin Cancer Res*
     2007;13:5411-17.

376. Sharifi N, Dahut WL, **Figg WD**. Secondary Hormonal Therapy for
     Prostate Cancer: What Lies on the Horizon? *Br J Urology*
     2008;101:271-4.

377. Sharif N, **Figg WD**. Androgen Receptor Modulation: Lessons
     Learned from Beyond the Prostate. *Cancer Bio Therap*
     2007;6:1358-9.

378. Chen X, Gardner ER, Gutierrez M, Kummar S, **Figg WD**.
     Determination of
     17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma
     by liquid chromatography with mass-spectrometric detection. *J
     Chromatogr B* 2007;858;302-6.

379. Li H, Raia V, Bertolini F, Price DK, **Figg WD**. Circulating
     Endothelial Cells as a Therapeutic Marker for Thalidomide in
     Combination Therapy with Chemotherapy Drugs in a Human Prostate
     Cancer Model. *Br J Urol* 2008;101:884-8.

380. Sharifi N, **Figg WD**, Dahut WL. Novel Agents for Prostate Cancer
     (Chapter 17). In Gulley JL, Dahut WL, Moul JW, Sandler HM (Editors)
     [Prostate Cancer: A Clinical Guide]{.underline}. Published by
     Lippincott, Williams and Wilkins, Philadelphia, PA 2008;167-73.

381. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M,
     Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, **Figg WD**,
     Sparreboom A. Association of the CYP1B1\*3 allele with Survival in
     Patients with Prostate Cancer Receiving Docetaxel. *Mol Cancer
     Therap* 2008;7:19-26.

382. Chu Z, Chen JS, Liau CT, Wang HM, Lin YC, Yang MH, Chen PM, Gardner
     ER, **Figg WD**, Sparreboom A. Oral Bioavailability of a Novel
     Paclitaxel Formulation (Genetaxyl) Administered with Cyclosporin A
     in Cancer Patients. *Anticancer Drugs* 2008;19:275-81.

383. Fine HA, Kim L, Albert PS, Duic JP, Ma H, Zhang W, Tohnya T, **Figg
     WD,** Royce C. A phase I trial of Lenalidomide in patients with
     Recurrent Primary Central Nervous System Tumors. *Clinical Cancer
     Res* 2007;13:7101-6.

384. Chen X, Gardner ER, Price DK, **Figg WD**. Development and
     Validation of an LC-MS Assay for Finasteride and its Application to
     Prostate Cancer Prevention Trial Sample Analysis. *J Chromatogr Sc*
     2008;46:356-61.

385. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM,
     Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J,
     Jones E, Chen CC, **Figg WD**. A Phase II Clinical Trial of
     Sorafenib in Androgen-Independent Prostate Cancer. *Clin Cancer
     Res* 2008;14:209-14.

386. **Figg WD**, Chau C, Small E (Editors). [Drug Management of
     Prostate Cancer]{.underline}. Published by Humana Publishing,
     Totowa, NJ, 2007, In press.

387. Aragon-Ching JB, Gillespie J, Price DK, Chuaqui R,
     Rodriquez-Canales J, Steinberg SM, Dahut WL, **Figg WD**. Lack of
     Prognostic Significance of Prostate Biopsies in Metastatic Androgen
     Indpendent Prostate Cancer. *Br J Urology*, 2007;100:1245-8.

388. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, Hancox
     A, Hong JA, Chen GA,, Kruchin E, Wright JJ, Rosing DR, Sparreboom
     A, **Figg WD**, Steinberg SM. Clinical and Molecular Response in
     Lung Cancer Patients Receiving Romidepsin. *Clin Cancer Res*
     2008;14:188-98

389. Jain L, Gardner ER, Venitz J, Dahut W, **Figg WD**. Development of
     a Rapid and Sensitive LC-MS/MS Assay for the Determination of
     Sorafenib in Human Plasma. *J Pharm Biomed Anal* 2008;46:362-7.

390. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
     Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff
     P, Heller G, Basch E, Kelly WK, **Figg WD**, Small EJ, Beer TM,
     Wilding G, Martin A, Hussain M. Design and Endpoints of Clinical
     Trials for Patients with Progressive Prostate Cancer and Castrate
     Levels of Testosterone. *J Clin Oncol* 2008;26:1148-59.

391. Hamada A, Sissung T, Price DK, Danesi R, Venzon D, Maeda K,
     Sparreboom A, Mitsuya H, Dahut WL, **Figg WD**. Effect of *SLCO1B3*
     haplotype on Testosterone Transport and Clinical Outcome in
     Caucasian Patients with Androgen-Independent Prostatic Cancer.
     *Clin Cancer Res* 2008;14:3312-8.

392. Hoque A, Goodman P, Ambrosone CB, **Figg WD**, Price DK, Kopp W, Wu
     X, Conroy J, Lehman TA, Santella RM. Extraction of DNA from Serum
     for High-Throughput Genotyping: Findings from Pilot Studies within
     the Prostate Cancer Prevention Trial. *Urol* 2008;71:967-70.

393. Gardner ER, Sparreboom A, Verweij J, **Figg WD**. Lack of ABC
     Transporter Autoinduction in Mice Following long-term Exposure to
     Imatinib. *Cancer Bio Ther* 2008;14:188-98.

394. Ge Y, Byun JS, De Luca P, Gueron G, Yabe I, Sadiq-Ali SG, **Figg
     WD**, Quintero J, Haggerty CM, Li QQ, DeSiervi A, Gardner K.
     Combinatorial Anti-leukemic disruption of Oxidative Homeostasis and
     Mitochondrial Stability by the Redox Reactive Thalidomide CPS49 and
     Flavopiridol. *Mol Pharmacol*. In press.

395. Di Lorezo G, **Figg WD**, Fossa SD, Mirone V, Autorino R, Longo N,
     Imbimbo C, Perdona S, Giordano A, Giuliano M, Labianca R, De
     Placido S. Combination of Bevacizumab and Docetaxel Pretreated
     Hormone Refractory Prostate Cancer: A Phase II Study. *Eur Urol*,
     In press.

396. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching J,
     Hawkins M, Sparreboom A, **Figg WD**. Randomized, Crossover
     Pharmacokinetic Study of Paclitaxel and ABI-007 in Patients with
     Advanceed Solid Tumors. *Clin Cancer Res* 2008;14:4200-5.

397. Sissung TM, Baum C, Deeken J, Price DK, Dahut W, Sparreboom A,
     **Figg WD**. ABCB1 genetic variation Influences the Toxicity and
     Clinical Outcome of Patients Treated with Docetaxel. *Clin Cancer
     Res*. In press.

398. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA,
     Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff
     P, Heller G, Basch E, Kelly WK, **Figg WD**, Small EJ, Beer TM,
     Wilding G, Martin A, Hussain M. Author Reply: Design and Endpoints
     of Clinical Trials for Patients with Progressive Prostate Cancer
     and Castrate Levels of Testosterone. *J Clin Oncol,* (Letter) In
     press.

399. Arlen PM, Bianco F, Dahut WL, D'Amico A, **Figg WD**, Freedland SJ,
     Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O.
     Prostate-Specific Antigen Working Group Guidelines on Prostate
     Specific Antigen Doubling Time. *J Urol* 2008;179:2181-5.

400. Arlen PM, Bianco F, Dahut WL, D'Amico A, **Figg WD**, Freedland SJ,
     Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O. Author
     Reply - Prostate-Specific Antigen Working Group Guidelines on
     Prostate Specific Antigen Doubling Time. *J Urol* 2008;179:2185-6.

401. Gao R, Price DK, Sissung T, Reed E, **Figg WD**. Ethnic Disparities
     in Americans of European Descent versus Americans of African
     Descent related to Polymorphic ERCC1, ERCC2, XRCC1 and PARP1. *Mol
     Cancer Therap* 2008;7:1246-50.

402. Gardner ER, Dahut WL, **Figg WD**. Quantitative Determination of
     Total and unbound Paclitaxel in Human Plasma following Abraxane
     Treatment. *J Chrom B* 2008;862:213-8.

403. **Figg WD**, Chau CH, Okita R, Preusch P, Tracy TS, McLeod H, Reed
     M, Pieper J, Knoell D, Miller K, Speedie M, Blouin R, Kroboth P,
     Koda-Kimble MA, Taylor P, Cohen J, Giacomini K. Pharm.D. Pathways
     to Biomedical Research: The National Institutes of Health Pharmacy
     Research Conference. *Pharmacotherapy* 2008;28:821-33.

404. Sharifi N, Hamada A, Sissung T, Danasi R, Venzon D, Gulley JL,
     Price DK, Dahut W, **Figg WD**. A Polymorphism in Transporter of
     Testosterone is a Determinant of Androgen Independence in Prostate
     Cancer. *Br J Urol*, In press.

405. Chen X, Gardner ER, **Figg WD**. Determination of the cyclic
     depsipeptide FK228 in human and mouse plasma by liquid
     chromatography with mass-spectrometric detection. *J Chrom B*
     2008;865:153-8.

406. Gardner E, Dahut W, **Figg WD**. Thalidomide and Thalidomide
     Analogs. In **Figg WD**, Chau C, Small E (Editors). [Drug
     Management of Prostate Cancer]{.underline}. Published by Humana
     Publishing, Totowa, NJ, 2007, In press.

407. Sissung T, **Figg WD**. Clinical Pharmacology and Pharmacogenetics
     in Prostate Cancer. In **Figg WD**, Chau C, Small E (Editors).
     [Drug Management of Prostate Cancer]{.underline}. Published by
     Humana Publishing, Totowa, NJ, 2007, In press.

408. Danish M, Sissung T, Price DK, **Figg WD**. Genetic Stability of
     Tumor Microenvironment. *Cancer Bio Ther* 2008;7:1-2.

409. Smith NF, Baker SD, **Figg WD**, Sparreboom A. Modulation of
     Erlotinib Pharmacokinetics in Mice by a Novel Cytochrome P450 3A4
     Inhibitor, BAS100. *Br J Cancer* 2008;98:1630-2.

410. Sharifi N, Dahut WL, **Figg WD**. The Genetics of
     Castrate-Resistant Prostate Cancer: What Can The Germline Tell Us?
     *Clin Cancer Res* 2008;14:4691-3.

411. Gulley JL, Aragon-Ching JB, Steinberg SM, Hussain MH, Sartor O,
     Higano C, Petrylak D, Chatta GS, Arlen PM, **Figg WD**, Dahut WL.
     Kinetics of Serum Androgen Normalization after Limited Androgen
     Deprivation Therapy in Non-Metastatic Prostate Cancer. *J Urol*. In
     press.

412. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley
     JL, Arlen PM, Wright JJ, Parnes H, **Figg WD**, Dahut WD.
     Osteonecrosis of the jaw (ONJ) in Castrate-Resistant Prostate
     Cancer (CRPC) Patients Receiving ATTP (Bevacizumab, Docetaxel,
     Thalidomide, and Prednisone). *Cancer Invest*. In press.

413. Gardner E, Ahlers C, Shukla S, Sissung T, Ockers S, Price DK,
     Hamada A, Robey R, Steinberg S, Ambudkar S, Dahut WL, **Figg WD**.
     Association of ABCG2 C421A Polymophism with Prostate Cancer Risk
     and Survival. *Br J Urol.* In press.

414. Chau CH, McLeod HL, **Figg WD**. Validation of Analytical Methods
     for Biomarkers Employed in Clinical Trials. *Clin Cancer Res*. In
     press.

415. Chau C, **Figg WD**. Angiogenesis in Prostate Cancer. In **Figg
     WD**, Chau C, Small E (Editors). [Drug Management of Prostate
     Cancer]{.underline}. Published by Humana Publishing, Totowa,
     NJ, 2007. In press.

416. Chau C, **Figg WD**. Preclinical Models. In Kelly WK, Halabi S
     (Editors). [Fundamentals of Oncology Clinical Trials]{.underline}.
     In press.

417. Wang W, **Figg WD**. Secondary BRCA1 and BRCA2 Alterations and
     Acquired Chemoresistance, *Cancer Bio Ther*. In press.

418. Flowers L, Wick J, **Figg WD**, McClelland RH, Shiber M, Britton
     JE, Ngo DK, Borders-Hemphill V, Zee J. U.S. Public Health Service
     Commissioned Corps Pharmacists: Making a Difference in Advancing
     the Nation's Health. *J Am Pharm Assoc*. In press.

419. Jain L, **Figg WD**. Polypharmacy in View of Advances in Cancer
     Treatment. *The Oncology* 2008:22:1055-63.

420. Chau C, **Figg WD**. Combining mTOR inhibiton with Metronomic
     Chemotherapy in Targeting Angiogenesis. *Cancer Bio Ther*, In
     press.

421. Miles J, Price DK, **Figg WD**. Temporal-Mediated FGFR1
     Independence: Implications for Targeting Candidate Molecules in
     Prostate Cancer. *Cancer Biol Ther*. In press.

422. Gulley J, Dahut WL, D'Amico A, **Figg WD**. Author Reply to
     Prostate Specific Antigen Doubling-Time Criteria. *J Urol*. In
     press.

423. Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L,
     Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L,
     McNally D, Chow C, Chen HX, Wright JJ, **Figg WD**, Kohn E.
     Combination Targeted Therapy with Sorafenib and Bevacizumab Results
     in Enhanced Toxicity and Antitumor Activity. *J Clin Oncol*
     2008;26:3709-14.

**Submitted**

424. Ge Y, L QQ, Yabe I, **Figg WD**, Quintero J, Haggerty CM,
     Gardner K. Functional Transcriptional Pathways and Biomarker
     Profiling of Novel Selective cytokine Inhibitory Drugs in
     Mitogen-Activated Leukemic Cells.

425. Sissung TM, Pekarz RL, Steinberg SM, Bates SE, Price DK, Hwang K,
     **Figg WD**, Sparreboom A. ABCB1 variants and QTc interval
     Prolongation Associated with the Cyclic Depsipeptide FK228.

426. Chau CH, Steinberg SM, Price DK, **Figg WD**. Identification of
     SUMO-4 polymorphism in cancer cell lines and prostate cancer.

427. Chau CH**,** Permenter MG, Price DK, **Figg WD**. Detection of
     HIF-1alpha polymorphisms in the NCI60 cell panel.

428. **Figg WD**, Cox MC, Thurman PW. Differences Between Business
     Leader and Healthcare Professional Reliance on Academic Research.

429. Monga M, Headlee D, Messman R, Elsayed Y, Murgo A, Melillo G, Woo
     W, Zhai S, Hwang K, **Figg WD**, Senderowicz A, Hollingshead M.
     Arbuck SG, Sausville EA. A Phase I Trial of Oral Perifosine with
     Different Loading Schedules in Patients with Refractory Neoplasms.

430. Marti GE, Stetler-Stevenson MA, Drbohlav N, White T, Staudt L,
     **Figg WD**, Tohnya T, Jaffe E, Dunleavy KM, Janik J, Wilson WH.
     Phase I Trial of 7-Hydroxystaurosporine (UCN-01) and Fludararbine
     Phosphate (FAMP) In Vivo Evidence of UCN-01 Induced Apoptosis in
     CLL.

431. Therapontos C, Erskine L, Gardner E, Li H, **Figg WD**.
     Vargesson N. Thalidomide induces limb-specifi defects by targeting
     vascular smooth muscle cell deficient blood vessels.

432. Mucci LA, Stark JR, **Figg WD**, Schumacher F, Li H, Abe M,
     Hennessey K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW.
     Polymorphism in Endostatin, an Angiogenesis inhibitor, and Prostate
     Cancer Risk and Survival: A Prospective Study.

433. Stein WD, **Figg WD**, Dahut WL, Stein AD, Hoshen MB, Price DK,
     Bates SE, Fojo T. Tumor Growth Rates Derived from Data for Patients
     on a Clinical Trial Correlate Strongly with Patient Survival. A
     Novel Strategy for Evaluation of Clinical Trial Data.

434. Gardner ER, Smith NF, **Figg WD**, Sparreboom A. Influence of the
     Dual ABCB1 and ABCG2 Inhibitor Tariquidar on the Disposition of
     Oral Imatinib in Mice.

435. Deeken J, Cormier T, Price DK, Steinberg SM, Tran K, Liewehr DJ,
     Hardenbol P, Dahut WL, Miao X, **Figg WD**. A Pharmaccogenetic
     Study of Docetaxel and Thalidomide in Patients with
     Androgen-Independent Prostate Cancer Using the New Affymetrix DME-T
     1.0 Genotyping Platform.

436. Clamp DA, Yu JJ, Gao R, Jett J, Zot H, Clump AG, Shockey M, Gannett
     P, Coad JE, **Figg WD**, Reed E, Flynn DC. A Single Nucleotide
     Polymorphism in AFAP-110 Enables it to Efficiently Activate cSrc.

437. Azad NS, Aragon-Ching JB, Dahut WL, Posades EM, Gutierrez M, **Figg
     WD**, Steinberg SM, Turner ML, Kohn EC, Kong HH. A Comparison of
     Dermatologic Toxicities Single Versus Combination Agent Anti-VEGF
     Therapy.

438. Dahut WL, Tohnya TM, Aragon-Ching JB, Woo S, Gulley JL, Arlen PM,
     Venitz J, Wright JJ, **Figg WD**. A Phase I Study of Oral CC-5013
     (Lenalinomide, Revlimid) in Patients with Refractory Metastatic
     Cancer.

439. **Figg WD**, Hussain MH, Gulley JL, Arlen PM, Aragon-Ching JB,
     Petrylak DP, Higano CS, Steinberg SM, Chatta GS, Parnes H, Wright
     JJ, Sartor O, Dahut WL. A Double Blind Randomized Crossover Study
     of Oral Thalidomide versus Placebo in Patients with Stage DO
     Androgen Dependent Prostate Cancer Following Limited Hormonal
     Ablation.

440. Chau CH, **Figg WD**. The Role of Peroxisome
     Proliferatior-activated Receptors in Prostate Cancer.

441. Sung SY, Hsieh CL, Law A, Zhau H, Pathak S, Multani AS, Lim S,
     Coleman IM, Wu LC, **Figg WD**, Dahut WL, Nelson P, Lee JK, Amin
     MB, Johnstone PA, Marshall FF, Chung LWK. Permanent cytogenetic and
     Gene Expression Changes in Cancer-Associated Stromal Cells under
     3-D co-culture that Promote Prostate Cancer Growth and Progression.

442. Woo S, Gardner ER, Chen XH, Ockers SB, Baum CE, Sissung TM, Price
     DK, Frye R, Peikarz RL, Bates SE, **Figg WD**. Population
     Pharmacokinetics of Cyclic Romidepsin in Patients with Cutaneous
     T-cell Lymphoma and Relapsed Peripheral T-cell Lymphoma.

443. Piekarz RL, Frye R, Turner M, Wright JJ, Allen S, Kirschbaum MH,
     Zain J, Prince M, Leonard J, Geskin L, Hutchins L, Craig M, Reeder
     C, **Figg WD**, Gardner ER, Chen X, Liewehr D, Steinberg S, Jaffe
     E, Stetler-Stevenson MA, Fojo AT, Bates SE. A Multi-Institutional
     Phase II Trial of HDAC Inhibitor Romidepsin as Monotherapy for
     Patients with Cutaneous T-cell Lymphoma.

444. Azad N, Perray A, Gardner E, Chen X, Graves C, Sarosy GA, Minasian
     L, Kotz H, Raggio M, **Figg WD**, Kohn EC. A Phase I Study of
     Paclitaxel and Continuous Daily CAI in Patients with Refractory
     Solid Tumors.

445. Ning YM, **Figg WD**, Dahut WL. Reversal of Docetaxel Resistance
     with Bevacizumab and Thalidomide.

446. Danish M, Gardner ER, **Figg WD**. Determination of the Histone
     Deacetylase Inhibitor MS-275 in Human Plasma by Liquid
     Chromatography with Mass Spectrometric Detection.

447. Luna JM, Thurman P, Wolfe M, Yagoda D, **Figg WD**. Administrative
     Costs of Health Insurance for Hematology-Oncology Private Practice.

448. Wolfe ME, Yagoda D, Thurman PW, Luna JM, **Figg WD**. NCI
     Designated Cancer Center Funding Not Influenced by Organizational
     Structure.

####### Over 350 Abstracts

> **Invited Presentations:**

1.  "The Pharmacokinetics of Immunotoxins" Georgetown University, School
    of Medicine, Washington, DC, December 1994.

2.  "Utilization of Pharmacokinetic Principles in Anticancer Drug
    Development" Louisiana State University Medical Center, Shreveport,
    LA, June 1995.

3.  "The Mutated Androgen Receptor and Its Role in the Development of
    Hormone Refractory Prostate Cancer" Uniformed Services University of
    Health Sciences, Medical School, Bethesda, MD, January 1996.

4.  "Role of Pharmacist in Government Research (i.e., NIH)" Albany
    College of Pharmacy, Albany, NY, February 1996.

5.  "Suramin in Prostate Cancer: The NCI's Experience" University of
    Indiana's 7th Annual Uro-Onc Meeting, New Orleans, LA, November
    1996.

6.  "Update on the Treatment of Stage D Prostate Cancer," University of
    Arkansas Cancer Center, Little Rock, AR, January 1997.

7.  \"Preclinical Screening of Angiogenesis Inhibitors,\" 1st Annual
    Invitational Oncology Pharmacy Conference, Newport Beach, CA,
    February 1997.

8.  "Thalidomide in the Treatment of Prostate Cancer," Johns Hopkins
    Oncology Center, Baltimore, MD, March 1997.

9.  "Inhibition of Angiogenesis," CaPCURE Annual Meeting, Tahoe, NV,
    September 1997.

10. "Phase II of Thalidomide in Androgen Independent Prostate Cancer,"
    4th Annual Angiogenesis Meeting, Hamilton, Bermuda, October 1997.

11. "Dilemmas in the Development of New Agents to Treat Hormone
    Refractory Prostate Cancer," Harvard Medical School, Boston, MA,
    February 1998.

12. "PSA as a Surrogate Marker In Metastatic Prostate Cancer," 2nd
    Annual Invitational Oncology Pharmacy Conference, Newport Beach, CA,
    February 1998.

13. "The Role of Angiogenesis Inhibitors in Prostate Cancer," Strategic
    Research Institute, Princeton, NJ, March 1998.

14. "Treatment of Stage D0 Prostate Cancer with Angiogenesis
    Inhibitors," Aberdeen University Medical School, Aberdeen, Scotland,
    June 1998.

15. "Validation of a Rat Aorta Angiogenesis Model," Nagoya Cancer
    Meeting, Nagoya, Japan, September 1998.

16. \"Tumor Markers as Surrogate Endpoints,\" American Association of
    Pharmaceutical Scientist, San Francisco, CA, November 1998.

17. "Clinical Development of Matrix Metalloproteinase Inhibitors," 1st
    International Symposium on Anti-Angiogenic Agents, Dallas, Texas,
    January 1999.

18. "Clonal Analysis of Trinucleotide Repeat in Androgen Receptor," 3rd
    Annual Invitational Oncology Pharmacy Meeting, Napa Valley,
    California, February 1999.

19. "Surrogate Endpoints of Antiangiogenesis Clinical Trials," Institute
    for International Research, Bethesda, MD, February 1999.

20. \"Trinucleotide Repeat in the Androgen Receptor,\" South West
    Oncology Group, Chicago, IL, July 1999.

21. \"Anticancer Drug Development Targeted towards Solid Tumors,\"
    Breast Cancer Think Tank, Chantilly, VA, July 1999.

22. \"Thalidomide in Solid Tumors,\" NCI Molecular and Clinical Grand
    Rounds, Bethesda, MD, September 1999.

23. \"Men\'s Health - Treatment of Prostate Cancer,\" University of
    Wisconsin Symposium, Milwaukee, WI, September1999.

24. \"Advances in the Treatment of Androgen Independent Prostate
    Cancer,\" American College of Clinical Pharmacy, Kansas City, MO,
    October 1999.

25. \"Thalidomide in Metastatic Prostate Cancer,\" Mt Sinai Cancer
    Center, New York, NY, November 1999.

26. \"Importance of Apoptosis in the Development and Treatment of
    Cancer,\" American Society of Hospital System Pharmacist, Orlando,
    FL, December 1999.

27. \"Angiogenesis as an Anticancer Target\" National Institutes of
    Health Clinical Center Grand Rounds, Bethesda, MD, December 1999.

28. \"Treatment Options for Metastatic Prostate Cancer,\" Cornell
    University Medical Center - New York Hospital Hematology/Oncology
    Grand Rounds, New York, NY, January 2000.

29. \"Species Specificity for Endostatin,\" University of Wisconsin
    Cancer Center/School of Pharmacy Grand Rounds, Madison, WI, January
    2000.

30. \"Moving MMP Inhibitors from Bench to Clinic,\" Invasion Metastasis
    Conference Japan/USA, Maui, HI, February 2000.

31. \"Development Plan for Cytostatic Anticancer Agents,\" Cell Biology
    Department Seminar Series, MD Anderson Cancer Center Grand Rounds,
    Houston, TX, February 2000.

32. \"AIPC - What Treatments are Available,\" Medical College of
    Virginia, Richmond, VA, February 2000.

33. \"Combination Therapy (Angiogenesis Inhibition, MMP Inhibition, and
    Chemotherapy) for the Treatment of Prostate Cancer,\" Cancer Center
    Grand Rounds, Albert Einstein Medical School, New York, NY, March
    2000.

34. \"Treatment Options for Metastatic Prostate Cancer,\" Seminars in
    Oncology, Howard University Medical School, Washington, DC, April
    2000.

35. "Clinical Pharmacology for Angiogenesis Inhibitors - Abstract
    Highlights" American Society of Clinical Oncology Annual Meeting,
    New Orleans, LA, April 2000.

36. "Identification of Analogs of Thalidomide that Inhibit Angiogenesis"
    VA Hospital University of Pittsburgh, Pittsburgh, PA, August 2000.

37. "Bioassay for Angiogenesis" North Shore University Medical Hospital,
    Manhasset, NY, September 2000.

38. \"Metabolism of Thalidomide\" Multiple Myeloma Foundation Round
    Table, Boston, MA, October 2000.

39. \"Treatment of Metastatic Prostate\" Novel Molecular Targets in the
    Treatment of Cancer, Buenos Aires, Argentina, October 2000.

40. \"Targeting Invasion and Metastasis in the Treatment of Cancer\"
    Novel Molecular Targets in the Treatment of Cancer, Buenos Aires,
    Argentina, October 2000.

41. \"Targeting Angiogenesis in the Treatment of Cancer\" NIH Research
    Festival, Bethesda, MD, October 2000.

42. \"Advances in the Treatment of Prostate Cancer\" University of
    California at Los Angeles Cancer Center, LA, Calif., November 2000.

43. \"Finding a Role for Angiogenesis Inhibitors in the Treatment of
    Prostate Cancer\" Cancer Chemotherapy Foundation, Mt Sinai, NY,
    November 2000.

44. \"Advances in the Treatment of Androgen Independent Prostate
    Cancer\" VA Hospital Kansas City, MO, November 2000.

45. \"Thalidomide: Place in Solid Tumor Therapy\" University of Kansas,
    Kansas City, MO, November 2000.

46. \"Screening for Angiogenesis Inhibitors\" Washington Hospital Center
    Cancer Center, Washington, DC, January 2001.

47. \"Novel Inhibitors of Angiogenesis\" 1st International Congress on
    Prostate Cancer, San Juan, PR, June 2001.

48. \"Isozymes Responsible for the Metabolism of Thalidomide\"
    International Congress of Therapeutic Drug Monitoring, Washington,
    DC, September 2001.

49. \"Developing Analogs of Thalidomide\" Los Angeles VA Hospital, Los
    Angeles, CA, October 2001.

50. \"Stage D0 Cooperative Trial for Prostate Cancer\" Seattle Urology
    Association, Seattle, WA, November 2001.

51. \"Finding a Clinical Role for Antiangiogenic Therapy\" Fred
    Hutchinson Cancer Research Center, Seattle, WA, November 2001.

52. \"Prostate Cancer: Treatment Options\" West Virginia University
    School of Pharmacy, Morgantown, WV, February 2002.

53. \"How to Form a Drug Development Program\" West Virginia University
    Cancer Center, Morgantown, WV, February 2002.

54. \"Evaluation of Endostatin in Human Saphenous Vein Model\" Cold
    Spring Harbor, NY, March 2002.

55. \"The Role of Circulating Endothelial Cells in Angiogenesis of a
    Solid Tumor\" North Dakota State University, Fargo, ND, March 2002.

56. \"Preclinical Models to Assess Angiogenesis\" International
    Conference on Prostate Cancer, Barcelona, Spain, April 2002.

57. \"New Agents Targeting Prostate Cancer\" International Conference on
    Prostate Cancer, Barcelona, Spain, April 2002.

58. \"Identification of Novel Agents to Inhibit Angiogenesis\" NIH
    Clinical Center Grand Rounds, Bethesda, Maryland, June 2002.

59. \"Angiogenesis Inhibitors in the Treatment of GU Cancers: Real or
    Fiction\" 2nd Annual GU Malignancy International Conference, St.
    Thomas, USVI, July 2002.

60. "The Business of Science: The Relationship between the Private
    Sector and the Public Sector" Columbia University School of
    Business, New York, NY, July 2002.

61. \"Pharmacogenetic variance in the Cytochrome P4502C19 Isozyme in
    patients with Prostate Cancer\" Schelling Conference, American
    Cancer Society, Santa Cruz, CA, September 2002.

62. "Herbal Therapies for Patients with Prostate Cancer" Alliance for
    the Prevention and Treatment of Prostate Cancer, Morristown, New
    Jersey, October 2002.

63. "Preclinical Models to Screen for Antiangiogenic Agents" Society of
    Biological Therapy, San Diego, CA, November 2002.

64. "Docetaxel plus Thalidomide compared with Docetaxel in patients with
    AIPC" Chemotherapy Foundation, New York, NY., November 2002.

65. "Combining Agents that Target Endothelial Cells with Cytotoxic
    Chemotherapy" LSU CE Program, New Orleans, LA, November 2002.

66. "Randomized Phase II Trial of Docetaxel plus Thalidomide vs
    docetaxel in Patients with AIPC" 2^nd^ International Summit of
    Opinion Leaders in GU Malignancy, St. Thomas USVI, January 2003.

67. "The Future of Angiogenesis Inhibition in the Treatment of Cancer"
    Baylor Medical School, Houston, TX, March 2003.

68. "Molecular Targeted Therapy for the Treatment of Cancer -- Drug
    Development Road Map" West Virginia University Medical School Grand
    Rounds, Morgantown, WV, March 2003.

69. "The Role of Taxotere in the Treatment of Metastatic Prostate
    Cancer" Roundtable on GU Oncologist, Palm Beach, FL, March 2003.

70. "Tumor Angiogenesis" NIH Pharmacy Department 8^th^ Annual CE
    Program, Bethesda, MD, May 2003.

71. "Drug Development for Targeted Anticancer Agents" University of New
    Mexico, Albuquerque, NM, June 2003.

72. "Thalidomide Plus Taxotere" ASCO Aventis Investigators Meeting,
    Chicago, IL, June 2003.

73. "Where do we go with agents that target endothelial cells as a
    Anticancer Therapy" Instituto Nacional de Cancer, Rio De Janeiro,
    Brazil, June 2003.

74. "Thalidomide and the Treatment of Kidney Cancer" Kidney Cancer
    Association, Chicago, IL, July 2003.

75. "Determining the Starting Dose for Phase 1 Trials" CBI's Conference
    on Maximizing Phase 1 Studies, Alexandria, VA, September 2003.

76. "Genetic Variables in Androgen Metabolism" NCI's Hormones in Cancer
    Conference, Hunt Valley, MD, October 2003.

77. "Angiogenesis Inhibitors in Prostate Cancer" American Urological
    Association Section Meeting, Boca Raton, FL, October 2003.

78. "Biomarkers in Cancer Trials" Institute for International Research,
    Phase I Trials in Oncology, Washington, DC January 2004.

79. "Thalidomide Analogs in Renal Cancer" 3^rd^ Annual Meeting on GU
    Cancers, Santa Barbara, CA February 2004.

80. "Microarray Analysis of Androgen Dependent and Androgen Independent
    Prostate Cancer" Androgen Metabolism Symposium, Keystone, CO March
    2004.

81. "Combining Angiogenesis Inhibitors with Chemotherapy in the
    Treatment of Pancreatic Cancer" Pisa, Italy April 2004.

82. "Antiangiogenesis Agents in the Treatment of Renal Cell Cancer" ASCO
    Annual Meeting, New Orleans, LA June 2004.

83. "Treatment Options for Metastatic GU Cancer" University of Iowa GU
    Conference, Iowa City, IA June 2004.

84. "Update on Angiogenesis Inhibitors in GU Cancer" 4^th^ Annual
    International Prostate Cancer Congress, Freeport, Bahamas, July
    2004.

85. "How are Pharmaceuticals Developed and Approved in the US" Columbia
    University's School of Public Health, August 2004.

86. "Pharmacogenetics of Prostate Cancer" Italian Society of
    Pharmacology, University of Pisa, Pisa, Italy, October 2004.

87. "Developing Anticancer Agents (Lead Compound to IND)" University of
    Delaware, Newark, DE, November 2004.

88. "Interactions between Anticancer Agents and Herbal Products" NCAM,
    Bethesda, MD, December 2004.

89. "Survival Update for the Combination of Thalidomide and Docetaxel in
    AIPC" ASCO Prostate Cancer Meeting, Orlando, FL, February 2005.

90. "Leon Goldberg Lecture -- Relationship between Anticancer Drug
    Development and Pharmacogenetics" American Society of Clinical
    Pharmacology and Therapeutics, Orlando, FL, March 2005.

91. "Angiogenesis as a Target for Prostate Cancer Drug Development"
    University of Michigan Department of Urology, Ann Arbor, MI, March
    2005.

92. "NCI's Direction in the Treatment of AIPC" National Complementary
    and Alternative Medicine Institute, Bethesda, MD, March 2005.

93. "Using Preclinical Models to Influence Anticancer Drug Development"
    Pharmaceutical Summit, Philadelphia, PA, March 2005.

94. "Using Preclinical Pharmacogenetics Information to Influence
    Clinical Development of Anticancer Agents" American College of
    Clinical Pharmacology, Myrtle Beach, SC, April 2005.

95. "Pharmacogenetics Influence in Healthcare Management" Delaware
    Valley Healthcare Association, Philadelphia, PA, April 2005.

96. "Combination of Thalidomide and Docetaxel in AIPC" Society of
    Urologic Oncology, San Antonio, TX, May 2005.

97. "Advances in the Treatment of Androgen Independent Prostate Cancer"
    COA Annual Meeting of the Public Health Service. Philiadelphia, PA,
    June 2005.

98. "Translating Research into Healthcare Outcomes" Asian Society of
    Pharmacy, Singapore, June 2005.

99. "Pharmacogenetics of Anticancer Drug Development" Asian Society of
    Pharmacy, Singapore, June 2005.

100. "Thalidomide in the Treatment of AIPC" National Cancer Center,
     Singapore, June 2005.

101. "Pharmaceutical Industry's Strategy in Developing New Agents"
     Columbia University's Public Health School, New York, NY, July
     2005.

102. "ABCG2 -- Polymophisms in this Transporter can Alter the
     Pharmacokinetics of Drugs" FASEB Saxon River, VT, July 2005.

103. "Endothelial Cells in Solid Tumors" Washington Hospital Center,
     Washington, DC, September 2005.

104. "Research Pharmacist's Role in Anticancer Drug Development"
     University of Southern California School of Pharmacy, Los Angeles,
     CA, October 2005.

105. "Synergy between Chemotherapy and Targeted Anticancer Agents"
     Molecular Oncology Conference, Crete, Greece, October 2005.

106. "The Relationship between Inflammation and Prostate Cancer"
     American College of Clinical Pharmacy, San Francisco, CA, October
     2005.

107. "Research within the Intramural Program at the National Institutes
     of Health" University of California San Francisco, CA, October
     2005.

108. "The importance of genetic Variances in Response to Anticancer
     Treatments" Health Disparity Conference, National Institutes of
     Health, November 2005.

109. "The Future of Pharmacy" University of Sydney, Sydney, Australia,
     November 2005.

110. "Rational Drug Design and Development" University of Sydney,
     Sydney, Australia, November 2005.

111. "The Value of Stem Cells in Medical Research" St. Johns Episcopal
     Church, McLean, VA, December 2005.

112. "Inflammation's Role in the Development and Progression of Prostate
     Cancer" NIH's Lecture Series for Practicing Physicians, May 2006.

113. "The Importance of Pharmacogenetics in the Treatment of Cancer of
     the Prostate" 15^th^ World Congress on Pharmacology, Beijing,
     China, July, 2006.

114. "Combination of Angiogenesis Inhibitor and Chemotherapy in the
     Treatment of AIPC" 6^th^ Annual Congress on Prostate Cancer, Boca
     Raton, FL, July 2006.

115. "Genetic Evidence of Evolution" St. Johns Episcopal Church, McLean,
     VA, August 2006.

116. "Public Policy and Healthcare Outcomes" Columbia University School
     of Public Health, New York, NY, September 2006.

117. "Development of Thalidomide as an Angiogenesis Inhibitor -- from
     Screening to the Clinic" The Angiogenesis Foundation's 4^th^ Annual
     International Conference, Boston, MA, October 2006.

118. "Development of Angiogenesis Inhibitors -- from Screening to the
     Clinic" eCheminfo InterAction Meeting, Bryn Mawr College,
     Philadelphia, PA, October 2006.

119. "Pathway for the Development of PharmD Independent Researchers"
     National Institutes of Health Conference on Pharmacy Research,
     December 2006.

120. "Career Options in Pharmacy" National Institutes of Health IRTA
     post-bac Program, January 2007.

121. "Clinical Pharmacologist: Supply and Demand" University of
     Minnesota College of Pharmacy Graudate Student Program, May 2007.

122. "Opportunities for Science at the NIH" University of Maryland
     Graduate Student Retreat, Hapers Ferry, WV, June 2007.

123. "Molecular Pharmacology of CPS49" Dartmouth College, Department of
     Pharmacology and Toxicology Annual Graduate Student Seminar,
     Hanover, NH, June 2007.

124. "Identification and Validation of Biomarkers in Cancer" American
     College of Clinical Pharmacology, Denver, CO, October 2007.

125. "The Impact of the Human Genome Project on Drug Development"
     Tyson's Corner Rotary Club, McLean, VA, November 2007.

126. "Pharmacogenetics: Ethnic Differences" American Associate of Cancer
     Research, Atlanta, GA, November 2007.

127. "Thalidomide in Solid Tumors" Chinese Clinical Pharmacologist NIH
     Meeting, Bethesda, MD, December 2007.

128. "Sorafenib in Prostate Cancer" Bayer Review of Sorafenib in Solid
     Tumors, Chicago, IL, April 2008.

129. "Review of the Last 5 Years of Nobel Prizes in Physiology and
     Medicine" St. John's Episcopal Church, McLean, VA, April 2008.

130. "Candidate Gene vs High Through Genotyping" Affymetrix, San
     Francisco, CA, April 2008.

131. "Use Your Degree to Make a Difference" Samford University
     Commencment Address, Birmingham, AL, May 2008.

132. "Best of GU Cancer Presentations at the 2008 ASCO Meeting" Best of
     ASCO Meeting, Los Angeles, CA, June 2008.

> **Research Funding and CRADA Support:**
>
> National Institutes of Health, National Cancer Institute, Clinical
> Pharmacology Program and Molecular
>
> Pharmacology Section, MOB - Intramural Funding - 7/92 - present - all
> projects
>
> élan Pharmaceutical Company - \$450,000 CRADA (#0139) - 1995-1996 -
> Principal Investigator
>
> "Clinical and Preclinical Development of Phenylbutyrate as an
> Anticancer Agent"
>
> NIH Office of Minority Health - \$1,631,000 - 1997-2000 - Principal
> Investigator "Determining the Correlation Between Androgen Receptor
> CAG Trinucleotide Repeat Length and Prostate Cancer Risk"
> Collaboration with Southwest Oncology Group
>
> American College of Clinical Pharmacy Oncology Fellowship - \$20,000 -
> 1998- Principal Investigator "Determination of CAG Repeat Length in
> the Exon 1 of the Androgen Receptor of Native American Men and
> Hispanic Men"
>
> Unrestricted Gift from Frank J. McGuigan Trust - \$20,000 - 1997 -
> Principal Investigator
>
> "Drug Development for Prostate Cancer"
>
> Unrestricted Gift from Henry Benach Foundation - \$5,000 - Principal
> Investigator
>
> \"Drug Development for Prostate Cancer\"
>
> Celgene Pharmaceutical Company -- CRADA (#01031) for development of
> CC5013 - \$460,000 - 2001 to 2008 - Principal Investigator
>
> American Biosciences, Inc. -- CRADA (#01892) for development of
> ABI-007 - \$49,000 - 2004 to 2007 - Principal Investigator
>
> American College of Clinical Pharmacy Oncology Fellowship - \$25,000 -
> 2002 to 2004 - Principle Investigator
>
> National Institutes of Health PO1 Grant " Molecular Analysis of the
> PCPT" - Actual \$776,000 over 5 years, Total for P01 \$27,000,0000
> 2005 to 2009 -- Co-Principal Investigator on Project 1 and Co-Leader
> of Core B
>
> Regeneron - CRADA 02054 "Effect of Vascular Endothelial Growth Factor
> (VEGF) Trap, a Protein Chimera Constructed from Two VEGF Receptors, on
> Tumor Growth and Metastasis in the Fetal Bone Metastasis Model" 06-05
> to 06-07 - Principal Investigator
>
> Novartis - M-CRADA 01297 "Research to Determine the Effect of Novartis
> Signal Transduction Inhibitor STI571 in LNCaP, a Prostate Cancer Cell
> Line 1-02 to 01-04 - Principal Investigator
>
> Locus Pharmaceutials - CRADA 01952 "Identification, Characterization
> and Development of Inhibitors that Act on Heat Shock Protein 90
> (HSP90) using Locus Pharmaceutical, Inc.'s Core Technology" 12-04 to
> 12-08 - Principal Investigator
>
> Guilford Pharmaceutical CRADA 00777 - 10-98 to 10-99 - Principal
> Investigator
>
> Immunex M-CRADA 00620 - 09-97 to 09-98 - Principal Investigator
>
> Center for Disease Control -- 8/07 to present -- Genetic Risk Factors
> for the Development of Cancer
>
> and Response to Cancer Treatment. \$750,000 -- Principal Investigator
>
> **Research Funding and CRADA Support (cont.):**
>
> NCI Director's Innovation Award. \$50,000 -- Principal Investigator
>
> **Patents and Licenses**
>
> [Human Saphenous Vein Angiogenesis Assay]{.underline} - CuraGen Corp.
> -- Licensed

[Thalidomide Analogs for Inhibition of Angiogenesis]{.underline}

E-282-2000/0-US-01 Filed application provisional

E-282-2000/0-PCT-02 Filed application PCT

E-282-2000/0-US-07 Filed application Nat stage

PCT/US02/05868

> 2-(2,4-Difluoro-phenyl)-isoindole-1,3-dione
>
> 2-(2,4-Difluoro-phenyl)-4,7-dimethyl-isoindole-1,3-dione
>
> 2-(2,4-Difluoro-phenyl)-4,5,6,7-tetrafluoro-isoindole-1,3-dione
>
> 2-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4,5,6,7-tetrafluoro-isoindole-1,3-dione
>
> 2-(2,4-Dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-isoindole-1,3-dione
>
> 2-(2,4-Dioxo-1-phenyl-1,2,3,4-tetrahydro-pyrimidin-5-yl)-4-nitro-isoindole-1,3-dione
>
> 2-(2,4-Dioxo-1,2,3,4-tetrahydro-pyrimidin-5-yl)-isoindole-1,3-dione
>
> 5-(1,3-Dioxo-1,3-dihydro-isoindol-2-yl)-5-ethyl-1-phenyl-pyrimidine-2,4,6-trione
>
> 5-Ethyl-5-(4-nitro-1,3-dioxo-1,3-dihyro-isoindol-2-yl)-1-phenyl-pyrimidine-2,4,6-trione
>
> 1-Cyclohexyl-5-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-5-ethyl-pyrimidine-2,4,6-trione
>
> 5-Ethyl-1-phenyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
>
> *Licensed Dec. 2002 from the NIH to Celgene Corp.*

[Thalidomide and Thio-thalidomide Analogs for Inhibition of Angiogenesis
and TNF-α]{.underline}

E-189-2003/0-EIR-00

E-189-2003/0- US-01

E-189-2003/0-PCT-02 Filed application PCT

E-189-2003/0-CN-08 Filed application Nat Stage

E-189-2003/0-US-03 Filed application US Pat application

PCT/US04/30506

2-(2,6-Dithioxo-piperidin-3-yl)-3-thioxo-2,3,3a,7a-tetrahydro-isoindol-1-one
(Z-3-099 1)

2-(2-Oxo-6-thioxo-piperidin-3-yl)-3a,7a-dihydro-isoindole-1,3-dione
(Z-2-085)

2-(1,3-Dithioxo-1,3,3a,7a-tetrahydro-isoindol-2-yl)-pentanedioic acid
dimethyl ester (Z-3-013 1)

> Acetic acid
> 6-(2,6-dioxo-piperidin-3-ylthiocarbamoyl)-cyclohexa-2,4-dienyl ester
> (Z-3-103)
>
> 2-(2-Hydroxy-6-methoxy-pyridin-3-yl)-isoindole-1,3-dione hydrobromide
> (Z-2-087)
>
> 2-(2,6-Dihydroxy-pyridin-3-yl)-isoindole-1,3-dione hydrobromide
> (Z-2-093)
>
> 2-(2,6-Dioxo-1-phenethyl-piperidin-3-yl)-isoindole-1,3-dione (Z-2-105)
>
> 2-(2,6-Dioxo-piperidin-3-yl)-pyrrolo\[3,4-*c*\]pyridine-1,3-dione
> (Z-2-115)
>
> 3-(3-Oxo-2,3-dihydro-isoindol-1-ylidene)-piperidine-2,6-dione
> (Z-2-141)
>
> 2-(2,6-Dimethoxy-pyridin-3-yl)-isoindole-1,3-dithione (Z-2-165)
>
> 2-(2,6-Dioxo-piperidin-3-yl)-4-hydroxy-isoindole-1,3-dione (Z-3-171)
>
> 2-Benzyl-3-benzylimino-2,3-dihydro-isoindol-1-one (Z-3-055)
>
> 2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid
> (Z-3-063)
>
> 2-(2,6-Dithioxo-piperidin-3-yl)-isoindole-1,3-dione (Z-3-073 1)
>
> 2-(2-Oxo-6-thioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one
> (Z-3-073 II)
>
> 2-(2,6-Dioxo-piperidin-3-yl)-benzo\[*de*\]isoquinoline-1,3-dione
> (Z-3-091)
>
> 2-(2,6-Dioxo-piperidin-3-yl)-3a,9a-dihydro-benzo\[*f*\]isoindole-1,3-dione
> (Z-3-097)
>
> (*R*) -
> 4,7,7-Trimethyl-3-oxo-2-oxa-bicyclo\[2.2.1\]heptane-1-carboxylic acid
> (2,6-dioxo-piperidin-3-yl)-amide (Z-3-106)
>
> (*S*) -
> 4,7,7-Trimethyl-3-oxo-2-oxa-bicyclo\[2.2.1\]heptane-1-carboxylic acid
> (2,6-dioxo-piperidin-3-yl)-amide (Z-3-109)
>
> Acetic acid 2-(2,6-dioxo-piperidin-3-ylcarbamoyl)-phenyl ester
> (Z-3-149)
>
> 3-(2,6-Dimethoxy-pyridin-3-yl)-benzo\[*e*\]\[1,3\]oxazine-2,4-dione
> (Z-3-147)
>
> 2-Cyclohex-2-enyl-isoindole-1,3-dithione (Z-2-157 I)
>
> Isoindole-1,3-dithione (Z-2-122)
>
> Pyrrolidine-2,5-dithione (Z-2-127)
>
> 2-(2,6-Dimethoxy-pyridin-3-yl)-isoindole-1,3-dione (Z-2-052)
>
> 2-(2-Oxo-6-thioxo-piperidin-3-yl)-isoindole-1,3-dione
>
> 3-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
>
> 2-(2,6-Dithioxo-piperidin-3-yl)-isoindole-1,3-dione
>
> 2-(2-Oxo-6-thioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one
>
> 2-(2,6-Dithioxo-piperidin-3-yl)-3-thioxo-2,3-dihydro-isoindol-1-one
>
> 2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid
> dimethyl ester
>
> 2-(1,3-Dithioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid dimethyl
> ester
>
> 2-(1-Oxo-3-thioxo-1,3-dihydro-isoindol-2-yl)-pentanedioic acid
>
> 6-Thioxo-piperidin-2-one
>
> Piperidine-2,6-dithione
>
> 2-Cyclohex-2-enyl-isoindole-1,3-dithione
>
> 2-Cyclohex-2-enyl-3-thioxo-2,3-dihydro-isoindol-1-one
>
> Isoindole-1,3-dithione
>
> 3-Thioxo-2,3-dihydro-isoindol-1-one

[Cytochrome 1B1 Polymorphism Kit for Assessing Activity to
Docetaxel]{.underline}

E-307-2005/0 EIR-00

E-307-2005/0-US-01 Filed application provisional

US Provisional Application No 60/716,439 filed 9/05

[ABCB1 Genotyping to Predict Microtubule-Stabilizing Agent Induced
Toxicity]{.underline}

E-237-2006/0-EIR-00

E-237-2006/0-US-01 Filed application provisional

[Tetrahalogenated Compounds useful as Inhibitors]{.underline}

US Provisional 60/798,098 Filed 13 April 06

E-080-2006

> 1-Cyclohexyl-5-ethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu977)
>
> 1-Ethyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu973)
>
> 1-Cyclohexyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu974)
>
> 5-Methyl-1-propyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu997)
>
> 1,5-Diethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu987)
>
> 5-Ethyl-1-isopropyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
>
> 1-Isopropyl-5-methyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu993)
>
> 1,5-Dimethyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu1000)
>
> 5-Ethyl-1-propyl-5-(4,5,6,7-tetrafluoro-1,3-dioxo-1,3-dihydro-isoindol-2-yl)-pyrimidine-2,4,6-trione
> (Gu998)
>
> N-(1-Ethyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu965)
>
> N-(1-Cyclohexyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu976)
>
> N-(1-Cyclohexyl-5-ethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu978)
>
> 2,3,4,5-Tetrafluoro-N-(5-methyl-2,4,6-trioxo-1-propyl-hexahydro-pyrimidin-5-yl)-benzamide
> (Gu1030)

N-(1,5-Diethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
(Gu1029)

> N-(5-Ethyl-1-isopropyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu992)
>
> N-(5-Ethyl-2,4,6-trioxo-1-propyl-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu1031)
>
> 2,3,4,5-Tetrafluoro-N-(1-isopropyl-5-methyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-benzamide
> (Gu1032)

N-(1,5-Dimethyl-2,4,6-trioxo-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
(Gu1016)

> N-(5-Ethyl-2,4,6-trioxo-1-phenyl-hexahydro-pyrimidin-5-yl)-2,3,4,5-tetrafluoro-benzamide
> (Gu984)
>
> **Staff Scientist Working with Dr. Figg**

Doug Price, Ph.D., 12/99 to present, Staff Scientist, Molecular
Pharmacology Section, NCI

> Alex Sparreboom, Ph.D., 11/02 to 7/06, Currently PI, St. Judes
> Childrens Research Hospital
>
> Erin Gardner, Ph.D., 4/08 to present, SAIC Pharmacologist, Clinical
> Pharmacology Program
>
> **Post-Doctoral Fellows and Visiting Fellows Trained Under Dr. Figg**
>
> Richard Lush, Ph.D., 10/94 to 12/97, Currently, Executive Director
> Clinical Research, H. Lee Moffitt
>
> Cancer Center
>
> Bradley Simmons, Ph.D., 9/95 to 4/97, Currently, Senior Analytical
> Chemist for US Pharmacopia
>
> Shannon Dixon, Ph.D., 9/95 to 10/00, Currently, High School Science
> Teacher

Kenneth Bauer, Pharm.D., Ph.D., 5/98 to 5/99, Currently, Associate
Professor and Head of Clinical

Pharmacology Core, Univ. of Maryland Cancer Center

> Helen H. Cho, Pharm.D., 4/97 to 8/98, Currently, Medical Manager,
> Roche Korea Co., Seoul, South
>
> Korea
>
> Jozsef Horti, M.D., Ph.D., 8/96 to 9/98, Currently, Associate
> Professor, Ntl Inst of Oncology, Budapest,
>
> Hungary
>
> Min Hee Kang, Pharm.D., M.S., 8/98 to 9/01, Currently, Assistant
> Professor, University of Southern
>
> California Keck School of Medicine
>
> Suoping Zhai, M.D., Ph.D., 6/98 to 11/03, Currently, Clinical
> Pharmacologist, Roche Pharmaceutical
>
> Huachun Chen, Ph.D., 8/98 to 12/98, Currently, Associate Director,
> Clinical Pharmacology, Eisai
>
> Medical
>
> Sonia Kim, Pharm.D., MS, 7/99 to 9/01, Currently, Clinical Pharmacist,
> Fairfax Hospital
>
> Waverly Woo, Pharm.D., Ph.D., 5/99 to 6/02, passed away 6/02
>
> Yuichi Ando, M.D., Ph.D., 9/99 to 10/02, Currently, Associate
> Professor, Nagoya Medical School,
>
> Nagoya, Japan
>
> Sitara Kommareddi, M.D., 7/99 to 5/00, Currently, Staff Surgeon,
> University of Arizona
>
> Eiichi Fuse, Ph.D., 4/00 to 4/01, Currently, Senior Clinical
> Pharmacologist, Kyowa Pharmaceutical, Inc.
>
> Gordon Macpherson, Ph.D., 11/01 to 4/04, Currently, Scientist, Human
> Genome Sciences, Inc.

Sylvia Ng, Ph.D., 11/01 to 5/04, Currently, Assistant Professor,
University of British Columbia, Canada

> Kyung Hwa Hwang, Ph.D., 3/02 to 7/06, Currently, Associate Professor,
> University of Southern
>
> California
>
> Michael Cox, Pharm.D., 9/02 to 1/06, Currently, Associate Director,
> Amgen, Inc.
>
> Nicola Smith, Ph.D., 10/03 to 4/06, Currently, Staff Pharmacologist,
> DTP, NCI
>
> Luca Paoluzzi, M.D., 8/03 to 7/04, Currently, Instructor Columbia
> University, New York
>
> Charity Scripture, Pharm.D., M.S., 4/04 to 1/06, Currently, Staff
> Scientist, NCI.
>
> Cindy Chau, Pharm.D., Ph.D., 9/04 to present, Molecular Pharmacology
> Section, NCI
>
> Haiqing Li, MD, Ph.D., 10/04 to 4/07, Currently, Staff Scientist in
> Technology Transfer Branch, NCI
>
> Amy Sion, Pharm.D., 6/06 to 3/07, Currently, Hospital Investigational
> Pharmacists
>
> Tania Alchalabi, M.D., 7/06 to 7/07, Currently, Resident in Family
> Practice, University of Michigan
>
> Xiaohong Chen, Ph.D., 9/06 to present, Clinical Pharmacology Program,
> NCI
>
> Haihao Sun, Ph.D., 7/07 to present, Clinical Pharmacology Program, NCI
>
> Maria Silvina Frech, Ph.D., 9/07 to 1/08, Currently, Fellow at
> Georgetown University
>
> Sukyung Woo, Ph.D., 1/08 to present, Clinical Pharmacology Program,
> NCI

**Medical Oncology and Urology Fellows Trained Under Dr. Figg**

> Alain Thibault, M.D., 7/93 to 1/94, Currently, Medical Officer,
> Regeneron Biotech
>
> Christopher Bowden, M.D., 1/94 to 7/94, Currently, Medical Officer,
> Genentech, Inc
>
> Roberto Bitton, M.D., 10/94 to 6/95, Currently, Coordinator of
> Oncology Program, Elea Laboratorio
>
> Yinong Liu, M.D., Ph.D., 1/02 to 7/03, Currently, Medical Oncologist
> in Private Practice, Danville, KY
>
> Michael Franks, M.D., 1/03 to 7/04, Currently, Assistant Professor,
> University of Pittsburgh, Department
>
> of Urology

Avi Retter, M.D., 7/03 to 7/05, Currently, Medical Oncologist in Private
Practice, New York, NY

> Edwin Posadas, M.D., 7/03 to 7/05, Currently, Instructor, University
> of Chicago School of Medicine
>
> Shenhong Wu, M.D., 7/05 to 7/06, Currently, Assistant Professor, SUNY
> at Stony Brook, NY
>
> Chris Ahler, M.D., 7/05 to 7/07, Currently, Associate Director,
> Bristol Myers Squibb Pharmaceutical
>
> Jeanny Aragon-Ching, M.D., 10/06 to 6/08, Currently, Assistant
> Professor, George Washington
>
> University
>
> Nima Sharifi, M.D., 7/07 to 3/08, Currently, Assistant Professor,
> Texas Southwestern University
>
> **Visiting Professors working with Dr. Figg:**
>
> Juliann Chen, Pharm.D., 7/02 to 9/02, Visiting Professor from the
> University of Illinois
>
> Romano Danesi, M.D., Ph.D., 8/03 to 9/03; 7/04 to 8/04; 7/05 to 8/05;
> 7/06 to 9/06; 7/07 to 9/07;
>
> 7/08 to 9/08; Visiting Professor from University of Pisca, Italy
>
> Amanda Corbett, Pharm.D., 9/04 to 9/04, Visiting Professor from
> University of North Carolina
>
> Casey Laizure, Pharm.D., 5/05 to 6/05, Visiting Professor from the
> University of Tennessee
>
> Akinobu Hamada, Ph.D., 8/05 to 7/07, Visiting Professor from Kumamoto
> University, Japan
>
> Valentina Rioa, Ph.D., 10/05 to 11/05, Visiting Scientist from the
> University of Milan, Italy
>
> Lisa Davis, Pharm.D., 5/06 to 5/06, Visiting Professor from
> Philadelphia College of Pharmacy
>
> Chiya Imamura, Ph.D., 11/07 to present, Visiting Professor from Keio
> University, Japan
>
> Antonello Di Paolo, Ph.D., 1/08 to 2/08, Visiting Professor from
> University of Pisca, Italy
>
> **Research Associates working with Dr. Figg:**
>
> Jing Yu, MD 7/98 to 7/99
>
> Razi Raziuddin, Ph.D., 4/99 to 2/00
>
> Patricia Fernandez, Ph.D., 10/99 to 12/00
>
> Misha Blagosklonny, MD, 7/99 to 7/01
>
> Erin Gardner, M.S., 7/06 to 4/08
>
> Weixin Wang, Ph.D., 10/07 to present
>
> **Graduate Students who completed their PhD Thesis under Dr. Figg:**
>
> Kenneth Bauer, Pharm.D. PhD., 5/96 to 5/99, Ph.D. Degree from the
> University of Pittsburgh;
>
> Currently, Associate Professor, University of Maryland Cancer Center.
>
> Thesis "The molecular and clinical pharmacology of
> carboxyamido-triazole, and a
>
> clinical trial in prostate cancer"
>
> Michelle Rudek, Pharm.D., Ph.D. 7/96 to 7/01, Ph.D. Degree from the
> Virginia Commonwealth
>
> University; Currently, Assistant Professor and Head of Analytical
> Core, Johns Hopkins
>
> University Cancer Center.
>
> Thesis "Evaluation of the pharmacokinetic-pharmacodynamic relationship
> for the matrix metalloproteinase inhibitory effect of COL-3 following
> oral administration to patients with refractory metastatic cancer"
>
> Nehal Lakhani, MBBS, 8/00 to 7/05 Ph.D. Degree from Virginia
> Commonwealth University;
>
> Currently, Medical Oncology Fellow, National Cancer Institute
>
> Thesis "Evaluation of the Pharmacokinetic-Pharmacodynamic
> Relationship, Metabolism and Plasma Protein Binding of the Novel
> Antitumor Agent, 2 Methoxyestradiol (2ME2), Following Oral
> Administration in Patients with Solid Tumors"
>
> Milin Acharya, M.S., 8/01 to 9/05, Ph.D. Degree Virginia Commonwealth
> University;
>
> Currently, Pharmacologists at Johnson and Johnson Pharmaceutical.
>
> Thesis "Clinical pharmacology of MS-275, a histone deacetylase
> inhibitor"
>
> Tanyifor Tohnya, Pharm.D., 8/01 to 12/07, Ph.D. Candidate -- did not
> complete, Virginia Commonwealth
>
> University; Currently, Clinical Pharmacologists at Genentech.
>
> Tristan Sissung, M.S., 7/03 to 5/08, Ph.D. Candidate, George
> Washington University.
>
> Thesis "Genetic factors that alter the pharmacodynamics of
> antineoplastic agents independent of
>
> alterations in pharmacokinetics"
>
> Da Zhang, M.S., 7/05 to 10/07, Ph.D. Candidate -- did not complete,
> Virginia Commonwealth
>
> University
>
> Chun Nie, M.S., 7/06 to 5/07, Ph.D. Candidate -- did not complete,
> Virginia Commonwealth University
>
> Lokesh Jain, M.Pharm., 7/06 to present, Ph.D. Candidate, Virginia
> Commonwealth University

Kristinia Cook, B.S., 8/05 to present, Ph.D. Candidate, Oxford
University

Rui Gao, M.S., 9/05 to present, Ph.D. Candidate, University of Maryland

Heather Pressler, B.S., 5/08 to present, Ph.D. Candidate, Johns Hopkins
University

> **Residents, Students, Laboratory Assistants under Dr. Figg:**

Natalie McCall, B.S., 7/92 to 2/97, Towson State University

> Sophia Boudoulas, B.S., 8/94 to 8/95, Ohio State University
>
> Sophia Boudoulas, B.S., 9/96 to 8/97, George Washington University
> School of Public Health
>
> Bernadette Allman, B.S., 2/94 to 7/94, University of Maryland

Bruce Waldrop, B.S., 1/94 to 2/94, Samford University School of Pharmacy

> Jennifer Stevens, B.S., 1/94 to 8/94, Cornell University
>
> Kara Ammerman, B.S., 5/94 to 8/94, University of Pennsylvania
>
> Nathan Ryan, 5/94 to 8/94, 5/95 to 8/95, 5/96 to 8/96 Bard College,
> Howard Hughes Summer Student
>
> Matthew Middleman, 1/95 to 8/95, Cornell University
>
> Barabara Soriano, B.S., 6/95 to 8/95, University of Pennsylvania
>
> Mary Anna Denman, 8/95 to 12/95, Cornell University
>
> Melissa Sutherland, 8/95 to 12/95, 5/96 to 8/96 Cornell University
>
> Alexandra Zellas, B.S., 9/95 to 1/98, Hood College
>
> Jordan Lisella, 1/96 to 5/96, Cornell University
>
> Valerie Makarick, 1/96 to 5/96, Cornell University
>
> Christina Giordano, 1/96 to 5/96, Cornell University
>
> Rima Putta, 1/96 to 5/96, Cornell University
>
> Jonathan Feuer, B.S., 7/96 to 8/97, Cornell University
>
> Yi Guo, 6/96 to 8/96, University of Manchester/George Washington
> University
>
> Yi Guo, B.S., 3/97 to 4/98, George Washington University
>
> Kathryn Getek, 7/96 to 8/96, 6/97 to 7/97 Princeton University, Howard
> Hughes Fellow
>
> Geeta Sagar, 9/96 to 12/96, Gallaudet University
>
> Judith Smith, 10/96 to 12/96, Albany College of Pharmacy
>
> Anne Negrin, 1/97 to 5/97, Cornell University
>
> Sangeeta Raja, M.S., 3/97 to 8/97, University of North Dakota
>
> Sangeeta Raja, M.S., 8/97 to 8/98, Ph.D. Candidate, University of
> Maryland
>
> Ifey Arah, B.S., 5/97 to 5/98, University of Maryland
>
> Carolyn Shih, 6/97 to 8/97, 6/98 to 7/98 Brown University

Victor Llorens, 6/97 to 9/97, Gaithersburg High School

> Neil Hithcock, 11/97 to 12/97, Samford University School of Pharmacy
>
> Belinda Kwong, 8/97 to 12/97, Cornell University
>
> Lilian Wang, 6/97 to 8/97, Princeton University
>
> Mike Leedom, B.S., 8/97 to 2/98, James Madison University
>
> Nicole Pavick, B.S., 8/97 to 1/98, Boston College
>
> Kristen Guest, 10/97 to 12/97, Penn State University
>
> Julian Reed, 6/98 to 8/98, Xavier University
>
> Margaret Johnson, 5/98 to 8/98, 6/00 to 8/00 University of Virginia
>
> Kelly Cude, B.S., 8/98 to 8/99, University of California, Davis
>
> John Lee, 7/98 to 8/98, University of California, Berkley
>
> Manina Kaur, 5/98 to 8/98, University of Maryland
>
> Manina Kaur, B.S., 6/99 to 8/99, University of Maryland School of
> Pharmacy
>
> Erwin Kruger, B.A., 8/98 to 9/01, Harvard University
>
> Josh Blumenfeld, 6/98 to 8/98, Charles E. Smith Jewish Day School
>
> Shahrzad Movafagh, B.S., 8/98 to 4/99, University of Maryland
>
> Nina Lee, 9/98 to 12/98, Cornell University
>
> Kristen Stathis, 9/98 to 12/98, Cornell University
>
> Samer Nuwayhid, B.S., 1/99 to 5/00, Samford University
>
> Jeff Montgomery, B.S., 8/99 to 5/00, Columbia University College of
> Physicians and Surgeons
>
> Cara Kurlander, 6/99 to 8/99, University of Chicago
>
> Lisa Meister, 6/99 to 8/99, Columbia University
>
> Brooke Haehl, B.S., 5/99 to 10/99, University of Virginia
>
> Michael Cox, B.S., 11/99 to 12/99, Ohio Northern School of Pharmacy
>
> Siiri Forbes, B.S., 1/00 to 8/02, University of Wisconsin
>
> Amanda Reed, 6/00 to 8/00, Groves City High School
>
> Catherine Morris, 10/99 to 6/002, Columbia University
>
> Michael Weiss, B.S., 5/00 to 9/00, University of Leipzig, Germany
>
> Patricia Ross, B.S., 8/00 to 9/00, Shenandoah University School of
> Pharmacy
>
> Michelle Becker, B.S., 10/00 to 11/00, University of Kansas School of
> Pharmacy
>
> Justin Brockbank, B.S., 12/00 to 8/01, Brigham Young University
>
> Samantha Smith, 10/00 to 12/00, Wittenberg College
>
> Kevin Haynes, B.S., 2/01 to 3/01, Ohio Northern School of Pharmacy
>
> Andrew Trella, B.S., 5/01 to 8/01, University of North Carolina,
> Chapel Hill School of Pharmacy
>
> Theressa Ferrara, B.S., 6/01 to 9/04 William and Mary College
>
> Melinda Brown, B.S., 10/01 to 11/01, Samford University School of
> Pharmacy
>
> Belinda Cheung, B.S., 11/01 to 12/01, University of Wisconsin School
> of Pharmacy
>
> Anna Vitebsky, 9/01 to 12/01, Cornell University
>
> Helene Bichel, B.S., 1/02 to 2/02, Shenandoah University School of
> Pharmacy
>
> Andrada Tomoaia-Cotisel, 6/02 to 8/02, Stanford University
>
> Christopher Orr, 7/02 to 8/02, Landen High School
>
> Bernard Lee, 6/02 to 8/02, Rutgers School of Pharmacy
>
> Erin Lepper Gardner, M.S., 8/02 to 7/06, Oxford University, UK
>
> James Wang, B.S. 11/02 to 12/02, Uniformed Health Services Medical
> School
>
> Shubh Sharma, B.S., 11/02 to 7/03, American University
>
> Lara Dunn, 1/03 to 8/03, Cornell University
>
> Drew Goodman, 9/03 to 5/04, Winston Churchill High School
>
> Elissa Brockbank, 6/03 to 8/03, 5/04 to 8/04 Brigham Young University
>
> Anna Vitebsky, B.S., 6/03 to 7/03, Columbia University Graduate School

Kevin Hicks, 5/03 to 10/03, University of Michigan School of Pharmacy

> Andrada Tomoaia-Cotisel, 6/03 to 8/03, Stanford University
>
> Roxane Fan, 6/03 to 11/03, St. John's Prep School
>
> Daniell Ahn, B.S., 6/03 to 8/03, University of Virginia School of
> Medicine
>
> Kathryn Peterson, 1/04 to 2/04, Samford University School of Pharmacy
>
> Arun Singh, B.S., 8/03 to 9/04, Howard Hughes Medical Institute
> Scholar, NCI
>
> And 3^rd^ year medical student, New Jersey Medical School
>
> Matthew Permenter, B.S., 2/03 to 1/06, Penn State University
>
> Lorna Graham, B.S., 10/03 to 11/03, California State University
>
> Arjun Achutuni, 9/03 to 5/04, Thomas Wootten High School
>
> Sarah Prasse, 1/04 to 9/04, Cornell University
>
> Brian Everist, 6/04 to 8/04, University of Kansas Medical School
>
> Andrew Daniels, 6/04 to 5/05, University of Maryland

Ashley Tran, 10/04 to 11/04, Western University School of Pharmacy

Gareth Peters, B.S., 2/04 to present, George Mason University

Kathy Compton, B.S., 9/04 to present, James Madison University

> Diana Roame, 1/04 to present, University of the District of Columbia

Michael Loggia, 8/04 to 1/05, Thomas Wootten High School

Katherine Cochrane, 10/04 to 8/05, Madeira High School

Caitlin Fennell, 10/04 to 6/05, Walter Johnson High School

Tracy Mak, 1/05 to 5/05, Cornell University

Andy Yost, 1/05 to 5/05, Cornell University

Laura Pang, 5/05 to 8/05, University of Pennsylvania

Vicky Tkacz, 5/05 to 8/05, Ohio State University

Calvin Kwon, 8/05 to 9/05, Langley High School

Sherrod Taylor, 7/05 to 8/05, University of Mississippi

Priyanka Goel, BS, 7/05 to 9/05, Carnegie Mellon University

Clint Hensley, BS, 8/05 to 9/05, San Diego State University

Erika Smith, BS, 1/06 to 8/08, Penn State University

> Saurabh Agarwal, 1/04 to 6/04, Cornell University
>
> Ritchie Longoria, 6/04 to 8/04, University of Tennessee School of
> Pharmacy
>
> Jennifer Christenson, 11/04 to 12/04, University of Houston School of
> Pharmacy

Matt Danish, B.S, 9/06 to 8/08, University of Rochester

Sandra Ockers, B.S., 6/06 to 7/08, Davidson College

David Jiang, 9/06 to 12/06, Colgate University

Julie Barber, B.S., 7/06 to 9/06, Georgetown University Graduate Program

Jake Beverage, B.S, 6/06 to 8/06, University of California at San
Francisco School of Pharmacy

Caitlin Baum, 5/06 to 2/07, University of Maryland

Michael Choi, 7/06 to 5/07, Thomas Jefferson High School

Ellie Shuo Hong, 6/06 to 8/06, Phillips Exeter Academy

Heather Tomaszewski, 5/06 to 8/06, Virginia Tech University

> Rui Gao, B.S., 7/06 to 9/06, University of Maryland Graduate Program
>
> Poliana Andrade, 9/06 to 12/06, University of California at Davis
>
> Martha Couch, 10/06 to 2/07, Broadneck High School
>
> Diana Ziscovici, 9/06 to 5/07, Walter Johnson High School
>
> Rebecca Nakles, B.S., 12/06 to 5/07, Georgetown University Graduate
> Program

Samantha Pula, 5/07 to 8/07, North Dakota State University School of
Pharmacy

> Shelby Davis, 5/07 to 8/07, Bowdin College
>
> Jennifer Miles, 5/07 to 8/07, NOVA South East School of Pharmacy
>
> Katy Thompson, 5/07 to 8/07, Georgetown College
>
> Arnie Lehto, 5/07 to 8/07, Finland High School
>
> Caitlin Baum, 6/07 to present, University of Maryland
>
> Stephen Pisle, 9/07 to present, University of Maryland
>
> Hanem Ali, 1/08 to present, Georgetown University
>
> Randy Ochs, 6/08 to 8/08, Churchill High School
>
> Heather Pressler, 11/07 to 4/08, Johns Hopkins University
>
> Melissa Gilden, 6/08 to 8/08, University of Maryland
>
> Jorge Luna, 6/08 to 8/08, Columbia University
>
> Maggie Wolfe, 6/08 to 8/08, Columbia University
>
> Daniel Yagoda, 6/08 to 8/08, Columbia University
>
> Bevin English, B.S., 8/08 to present, Davidson College
>
> Seun Ajiboye, B.S., 7/08 to present, Duke University
>
> Craig Vargo, 6/08 to 8/08, Purdue University
>
> Shandiz Shahbazi, 6/08 to 8/09, Oakton High School
>
> Sarah Prasse, M.S., 6/08 to present, Georgetown University
>
> Joey Miles, B.S., 6/08 to 8/08, Georgetown College

##### Ad Hoc Tenure/Promotion Reviews:

University of Kentucky

University of Tennessee

West Virginia University

University of Southern California

University of Connecticut

Purdue University

Duke University

Johns Hopkins University

University of Illinois at Chicago

University of California at San Diego

University of Maryland

University of Georgia

University of Minnesota

**Grant or Program Review Committees:**

> Adult AIDS Clinical Trials Group, Pharmacology Grant Review Committee
> (1995)
>
> Department of Defense's, Grant Review Committee on Breast Cancer
> (1996)
>
> United Kingdom\'s Cancer Research Campaign, Grant Reviewer (1999-2008)
>
> Italian Association for Cancer Research, Grant Reviewer (2002-2003)
>
> Department of Defense, Ovarian Cancer Grant Review Committee (2002)
>
> North Carolina Biotechnology Awards, Grant Reviewer (2003)
>
> Maryland Biotechnology Awards, Grant Reviewer (2003)
>
> Austrian Foundation for Scientific Development, Grant Reviewer (2004)
>
> Avon-NCI Breast Cancer Progress Grant, Project Reviewer (2004)
>
> Japan Society for Promotion of Science Fellowship Grant, Reviewer
> (2004)
>
> Department of Defense, Prostate Cancer Integration Grant Committee
> (2004)
>
> Grant Reviewer (2006)
>
> American College of Clinical Pharmacy's Research Institute, Grant
> Priority Committee (2004-2005)
>
> Johns Hopkins University's Master in Biotechnology Graduate Selection
> Committee (2004)
>
> Japan Society for the Promotion of Science -- Fellowship Selection
> Committee (2004)
>
> National Institutes of Health Study Section (End Organ Disease) Grant
> Reviewer (2004)
>
> Ministry of Health and Biomedical Research Council, Grant Reviewer,
> Singapore (2005, 2008)
>
> NCI's Preclinical Pharmacology Extramural Grants Reviewer (2004)
>
> Austrian Science Fund, Grant Reviewer (2005)
>
> Cancer Research UK, Grant Reviewer (2005)
>
> ACCP Research Institute
>
> Chair of the Pharmacotherapy Grant Review Committee (2005)
>
> Chair of the Hematology Oncology Grant Review Committee (2005)
>
> Chair of the Investigator Development Award Review Committee (2005)
>
> Reviewer -- Career Development Award (2005 - 2006)
>
> Reviewer - Fellowships in Oncology (1994 - 2001)
>
> Reviewer - Grants in Oncology (1995 - present)
>
> Chair, Grants and Fellowship Selection Committee (2006)
>
> National Eye Institute, NIH, Board of Scientific Council, Intramural
> Site Visit Committee
>
> For the Laboratory of Retinal Cell and Molecular Biology (2005)
>
> West Virginia University Intramural Grant, Grant Reviewer (2006)
>
> United Kingdom's Breast Cancer Campaign, Grant Reviewer (2006)
>
> Austria Competence Center for Excellent Technologies, Grant Reviewed
> (2007)
>
> The Wellcome Trust, Grant Reviewer (2007)
>
> Rain Medical Research Foundation (The University of Western
> Australia), Grant Reviewer (2007)

**Grant or Program Review Committees (cont.):**

> Christian Doppler Research Association, Austria, Grant Reviewer (2007)
>
> National Medical Research Council, Singapore, Grant Reviewer (2007)
>
> Isreal Science Foundation, Tel Viva, Grant Reviewer (2008)
>
> **Clinical Trials in Which Dr. Figg is Principal Investigator or
> Protocol Chair:**

95-C-0178 A Randomized Phase II Study of Oral Thalidomide in Patients
with Hormone Refractory Prostate Cancer

95-C-0161 -- A Protocol to obtain Blood, Urine, and other Tissue samples
for Research Purposes to Investigate Micrometastases and the Presence of
PSA in the Urine

00-C-0080 - A Double Blind Randomized Crossover Phase III Study of Oral
Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent
Prostate Cancer Following Limited Hormonal Ablation

01-C-0256 - A Phase I Trial of 2-Methoxyestradiol (2ME2), an
Angiogenesis Inhibitor, in Patients with Solid Tumors

02-C0083 - A Multidose Phase I Study of Oral CC5013, a Thalidomide
Derivative, in Patients with Refractory Metastatic Cancer

02-C-0149 - A Phase I Trial of High Dose Ketoconazole plus Weekly
Docetaxel in Metastatic Androgen Independent Prostate Cancer

02-C-0138 - Retrospective analysis of CYP2C19 genotype in Cancer
Patients enrolled on Clinical Trials with Thalidomide at National Cancer
Institute to Assess the in vivo Metabolisms, Pharmacokinetics and
Pharmacodynamics of Thalidomide

02-C-0161 -- Retrospective Analyis of Promoter Polymorphism of UGT1A1
Gene in Cancer Patients Enrolled on Clinical Trials with Flavopiridol at
the National Cancer Institute to Assess the Pharmacokinetics and
Pharmacodynamics of Flavopiridol

03-C-0153 - Retrospective analysis of endostatin genotype in prostate
cancer patients to assess the association of a single nucleotide
polymorphism (D104N) in endostatin and prostate cancer

03-C-0242 - Pharmacological Analysis of Human Samples Collected in
Clinical Trials Performed Outside of the Intramural National Cancer
Institute

04-C-N279 - Retrospective Analysis of Drug Metabolizing Genotype in
Cancer Patients and Correlation with Pharmacokinetic Data

04-C-0132 - A Phase II Trial Combining Estramustine, Docetaxel, and
Thalidomide in Patients with Androgen-Independent Metastatic Prostate
Cancer

04-C0257 - A Phase II Trial of Docetaxel, Thalidomide, Prednisone, and
Bevacizumab in Patients with Androgen-Independent Prostate Cancer

04-C0280 - Randomized, Crossover, Pharmacokinetic study of Paclitaxel
and ABI-007 in Patients with Advanced Solid Tumors

05-C-N090 - Analysis of ABCG2 genotype in Gleevec treated Cancer
Patients to assess the Association of a Single Nucleotide Polymorphism
(C421A) in ABCG2 and Response to Treatment

07-C-0059 - A Phase II Study of AZD2171 in metastatic Androgen
Independent Prostate Cancer

07-C-0100 - Collection of Blood from Patients with Prostate Cancer